946

http://journals.tubitak.gov.tr/medical/

Turkish Journal of Medical Sciences Turk J Med Sci(2014) 44: 946-954© TÜBİTAKdoi:10.3906/sag-1310-77

Discovering missing heritability and early risk prediction for type 2 diabetes: a new perspective for genome-wide association study analysis with the Nurses’ Health Study

and the Health Professionals’ Follow-Up Study

Hüsamettin GÜL1,*, Yeşim AYDIN SON2, Cengizhan AÇIKEL3

1Department of Medical Informatics, Gülhane Military Medical Academy, Etlik, Ankara, Turkey2Department of Health Informatics, Informatics Institute, Middle East Technical University, Ankara, Turkey

3Department of Biostatistics, Gülhane Military Medical Academy, Etlik, Ankara, Turkey

* Correspondence: hgul23@gmail.com

1. IntroductionType 2 diabetes is a complex disease that is characterized by insulin resistance in peripheral tissues and dysfunction in insulin secretion. Type 2 diabetes is a major public health problem, and its prevalence is increasing at an alarming rate worldwide. It has been estimated that 371 million people are already affected by type 2 diabetes, and the number is projected to reach 552 million by 2030 (1).

The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors (2,3). Some risk factors, such as diet and obesity, are under personal control; however, genetic factors are not (4). Although the rise in type 2 diabetes prevalence can be mostly attributed to changes in diet and lifestyle, there is strong evidence of a genetic basis for type 2 diabetes (2). However, genetic risk factors have been found to have lower predictive values when compared to phenotype variables such as body

mass index (BMI), familial diabetes history (FAMDB), high blood pressure (HBP), and cholesterol (CHOL) (5,6). Furthermore, the additive contribution of genetic studies using single nucleotide polymorphisms (SNPs) to phenotype variables was found to be almost negligible in several studies (5–12). Because numerous genetic and nongenetic risk factors interact in the causation of type 2 diabetes, the predictive ability of genetic models will likely remain modest.

At present, the clinical use of genetic testing for type 2 diabetes prediction in adults is not recommended (13). Phenotypic risk factors have a higher predictive ability with area under the curve (AUC) values of 0.70–0.90, but these are in middle or later ages when the reversibility of factors is low. Therefore, a model to predict the risk score for type 2 diabetes in the early stages is needed. Additionally, as prediabetic individuals usually remain undiagnosed and

Background/aim: Despite the rise in type 2 diabetes prevalence worldwide, we do not have a method for early risk prediction. The predictive ability of genetic models has been found to be little or negligible so far. In this study, we aimed to develop a better early risk prediction method for type 2 diabetes.

Materials and methods: We used phenotypic and genotypic data from the Nurses’ Health Study and Health Professionals’ Follow-up Study cohorts and analyzed them by using binary logistic regression.

Results: Phenotypic variables yielded 70.7% overall correctness and an area under the curve (AUC) of 0.77. With regard to genotype, 798 single nucleotide polymorphisms with P-values of lower than 1.0E-3 yielded 90.0% correctness and an AUC of 0.965. This is the highest score in the literature, even including the scores obtained with phenotypic variables. The additive contributions of phenotype and genotype increased the overall correctness to 92.9% and the AUC to 0.980.

Conclusion: Our results showed that genotype could be used to obtain a higher score, which could enable early risk prediction. These findings present new possibilities for genome-wide association study analysis in terms of discovering missing heritability. These results should be confirmed by follow-up studies.

Key words: Type 2 diabetes, genome-wide association study, single nucleotide polymorphism, Affymetrix, binary logistic regression, ROC curve

Received: 21.10.2013 Accepted: 03.01.2014 Published Online: 24.10.2014 Printed: 21.11.2014

Research Article

947

GÜL et al. / Turk J Med Sci

untreated, identifying new methods using the genotype for the screening and prediction of risk factors is very important. The early prediction of risk factors may help patients to make lifestyle modifications in connection with preventable risk factors, such as obesity (14).

Genome-wide association studies (GWASs) have been widely used to investigate the role of the genotype in the development of diseases. Although many studies have been conducted to uncover the heritability of type 2 diabetes, only a small proportion of genetic heritability can be explained by the variants identified. GWASs have shown significant genome-wide associations with type 2 diabetes at 44 susceptibility loci so far (15). The current type 2 diabetes risk variants explain only about 5%–10% of the genetic basis of type 2 diabetes; much of the genetic basis remains unexplained (16,17).

Most of these studies used logistic regression for the analysis of genetic variables. However, the maximum number of SNPs used was 42, and C-statistics results (AUC) for the genotype were lower than 0.60 (5–12). In the course of our GWAS analysis of Nurses’ Health Study (NHS) and Health Professionals’ Follow-up Study (HPFS) data, we realized that sensitivity, specificity, and C-statistics increased with the number of SNPs. As we used genotype data for the whole genome instead of a finite number of SNPs, unlike previous studies, a high number of SNPs were included in the analysis. The highest prediction risk scores and AUCs for type 2 diabetes in the literature, even when phenotype studies are included, were achieved in this study using the 798 SNPs selected with P-values of less than 1.0E-3 for the model. Our findings demonstrate the importance of genotype in the prediction of type 2 diabetes, which has been previously disregarded.

2. Materials and methods 2.1. Study populationThe NHS and HPFS are well-characterized cohorts of nurses and health professionals, conducted in order to identify novel genetic factors that contribute to type 2 diabetes through large-scale, GWASs and to investigate the role of environmental exposure on the development of type 2 diabetes. The NHS and HPFS cohorts are part of the Gene Environment Association Studies initiative (GENEVA, http://www.genevastudy.org). The NHS was established in 1976, and the HPFS study was started in 1986. Participants of the NHS and HPFS completed a mailed questionnaire on their medical history and lifestyle. Blood was collected in 1989–1990 for the NHS and in 1993–1995 for the HPFS. Genotyping was completed in December 2008 for the NHS and in March 2009 for the HPFS. Lifestyle factors, including smoking, menopausal status and postmenopausal hormone therapy, and body weight, have been updated by validated questionnaires every 2 years.

Participants meeting the following criteria were excluded from the study: 1) those with other types of diabetes (65 NHS, 68 HPFS); 2) those belonging to races other than white (61 NHS, 100 HPFS); 3) HapMap controls (45 NHS, 29 HPFS); and 4) first-degree relatives (15 NHS, 14 HPFS). The final sample included 3248 (1769 controls and 1479 cases) for the NHS and 2391 (1277 controls and 1114 cases) for the HPFS. The current analysis includes SNPs mapped to chromosomes 1 through 23, as annotated based on the Affymetrix Genome-Wide Human SNP Array 6.0 (GeneChip 6.0). 2.2. Phenotypic variablesBMI has been shown to be the most important phenotypic variable in risk prediction of type 2 diabetes. BMI data were continuous in our study, and we converted them to binary using threshold levels that were calculated separately for males and females using the Youden Index (YI = sensitivity + specificity – 1) against the status of diabetes. We found BMI threshold levels of 26.3 kg/m2 for females and 27.1 kg/m2 for males that maximized the YI. Other phenotypic data including FAMDB, CHOL, and HBP were binary.

We also analyzed other phenotypic variables. While sex, polyunsaturated fat intake, trans fat intake, and magnesium intake were statistically not important, smoking, activity levels, postmenopausal hormonal status, alcohol, cereal fiber intake, heme iron intake, and glycemic load were found to be significantly related to diabetic status (data not shown). However, since these variables mostly depend on individual declaration, they are subjective. The contribution of these variables to classification and the AUC were negligible; therefore, we excluded them from the analysis for clarity.2.3. Software Analyses were conducted using PLINK and SPSS 15.0 for Windows. Amelia software was used to fill in missing values, and R was used for graphical presentation of quantile plots and Manhattan plots (www.r-project.org).

PLINK version 1.07 was used to analyze genome-wide data (http://pngu.mgh.harvard.edu/~purcell/plink). We merged NHS and HPFS data first. SNPs that met any of the following criteria were excluded from the analysis: 1) minor allele frequencies (MAF) of <0.05; 2) call rate of <95%; 3) P for Hardy–Weinberg equilibrium of <0.001; and 4) missing rates 0.1. After applying the QC filter, 642,576 SNPs remained for the analyses. 2.4. Binary logistic regressionWe performed binary logistic regression (BLR) using NHS and HPFS genotypic and phenotypic data via SPSS to test the associations of the genotypic and phenotypic risk scores with diabetes. We coded genotypes for common allele homozygotes, heterozygotes, and rare allele

948

GÜL et al. / Turk J Med Sci

homozygotes separately for analysis. We evaluated model discrimination by using C-statistics (areas under receiver operating characteristic curves, ROC-AUCs), which were calculated for the predicted risk of the logistic regression model.

We used SNPs with P-values of less than 1.0E-3. There were 886 SNPs with P-values below this level. However, we excluded SNPs if the missing allele number was greater than 50 (patients), except for rs10739592, since it had the lowest P-value (2.08E-14). It had 99 missing alleles. To fill in the missing alleles, we used the Amelia toolbox for imputation (18). The result of the imputation was validated by comparing ‘before’ and ‘after’ P-values of SNPs and observing the relative distribution density of the original data set and the imputed data set.

3. Results3.1. The clinical characteristics of the participantsThe clinical characteristics of the study populations are presented in Table 1. We performed a genome-wide analysis of NHS and HPFS participants. The frequency distribution of the P-value of the SNPs is given in Table 2. The P-values of 886 SNPs were less than 1.0E-03. The distribution of P-values for all SNPs (642,576) versus chromosomal distribution is shown as a Manhattan plot in Figure 1. Chromosomes, P-values, odds ratios, and MAF values of 798 SNPs are provided in the Appendix (on the journal’s website). Quantile–quantile (QQ) plots of P-values of SNPs are given against the expected P-values in Figure 2. We accepted 1.0E-3 as the threshold level to determine which SNPs would be included in the analysis (Figure 2). Initially, 886 SNPs were considered; after a quality check for missing criteria, 798 SNPs were used.3.2. BLR analysis of phenotypeThe analysis results of phenotype variables of the NHS and HPFS data sets are presented in Table 2. The summary of BMI is also listed in Table 3 as a continuous variable. As noted in Section 2, BMI was converted to a binary form before BLR analysis. Type 2 diabetes patients had significantly higher BMIs than the controls. BMI was strongly associated with type 2 diabetes; the odds ratio for

BMI was 3.86. Other important phenotypes were FAMDB, HBP, and CHOL. Their P-values and odds ratios are also given in Table 4. The combined effect of these 4 phenotype variables yielded an overall classification of 70.7% and an AUC of 0.77. We also compared rs10739592, which had the lowest P-value in GWAS analysis, with phenotypic variables. It should be noted that rs10739592 alone (OR: 1.34, P-value: 2.08E-14) increased the overall prediction by only 2.84%. The composite effect of phenotypic variables was less than the sum of the individual effects of each variable alone due to the effect of overlap.

We were able to predict individual risk scores using the following formula with constants obtained from logistic regression analyses of familial diabetes history, high blood pressure, cholesterol, and BMI.

Table 1. Clinical characteristics of the participants. Data presented as mean ± SD.

  Type 2 diabetes Control subjects

n (male/female) 1114/1479 1277/1769Age (years) 57.42 ± 7.72 57.12 ± 7.66BMI (kg/m2)Female 29.91 ± 5.76 25.39 ± 4.83Male 27.89 ± 4.14 25.21 ± 2.82

Table 2. P-value distribution of SNPs (before filtering of missing alleles, see Section 2).

P-value Cumulative frequency Frequency

<1.0E-11 1 11.0E-10 6 51.0E-09 6 01.0E-08 6 01.0E-07 10 41.0E-06 29 191.0E-05 132 1031.0E-04 886 754

–log

10 (ρ

)

1 2 3 4 5 6 8 10Chromosome

12 14 17 21

14

12

10

8

6

4

2

0

Figure 1. Manhattan plot of the point-wise P-values for the 642,576 SNP loci of the NHS and HPFS data sets.

949

GÜL et al. / Turk J Med Sci

exp(-1,579+famdb+1,132+hbp×0,862+chol×0,556+BMI×1,351

1+exp(-1,579+famdb+1,132+hbp×0,862+chol×0,556+BMI×1,351P=

The C-statistics (AUC) value for the 4 phenotype variables was found to be 0.77 ± 0.003. 3.3. BLR analysis of genotypeBecause the number of SNPs (798) is high and is unusual for BLR, as reported in the literature, we used a different approach to evaluate the effect of genotype on prediction scores and AUC. First, we grouped SNPs according to their P-values. Three groups of SNPs with P-values of less than 1.0E-4 yielded a maximum prediction score of 67.4% and an AUC of 0.735; 680 SNPs with P-values between 1.0E-04 and 1.0E-03 yielded a prediction score of 87.7% and an AUC of 0.947. When we used an incremental approach, the first 3 groups containing 118 SNPs with P-values of less than 1.0E-4 yielded prediction scores that were lower than

that of the fourth group (Table 5). This showed that more SNPs should be included for higher prediction rates and explained why previous studies in the literature that used a maximum of 40 SNPs obtained lower predictive values. In addition, we tested how various threshold levels in BLR analysis affected the prediction score and AUC (Table 6). The threshold level was chosen to be 0.5 by default in BLR analysis. When the threshold level increases, negative predictive value increases, positive predictive value decreases, and AUC does not change (Table 6).

We also investigated the additive contribution of phenotypes to the model built from genotyping data. The addition of 4 phenotypes (BMI, FAMDB, CHOL, and HBP) increased the prediction score from 90.0% to 92.9% and the AUC from 0.965 to 0.980 (Figure 3).

In addition, we found important differences between females and males in SNPs corresponding to the transcription factor-7–like 2 (TCF7L2) gene (Table 7). We found that the TCF7L2 gene was more determinative in males than in females. Although the TCF7L2 gene is one of the most significant genetic marker associated with type 2 diabetes mellitus risk (19), there is no information in the literature about the relationship between the TCF7L2 gene and sex. This finding is important when interpreting literature on interethnic differences that do not mention sex.

4. DiscussionDevelopment of genotype-based prediction will help us in the early prediction, identification, and prevention of type 2 diabetes. We showed that genotype-based predictions for type 2 diabetes yielded as high a score as phenotype-based methods. We obtained 90.0% prediction correctness, and the AUC was 0.965 with only genotype (SNP) variables. According to our knowledge, this is the highest score reported in the literature for risk prediction of type 2 diabetes.

GWAS has facilitated the understanding of the genetic basis of complex traits; it is a powerful method for the detection of genetic variations that predispose individuals

Obs

erve

d –l

og10

(ρ)

1 20 3 4 5 6Expected –log10 (ρ)

14

12

10

8

6

4

2

0

Figure 2. Quantile-quantile plots of SNP P-values in (NHS+HPFS) GWAS analysis. The x-axis is –log10 of the expected P-values and the y-axis is –log10 of the observed P-values. Detaching point from the expected –log10 is nearly 1.0E-3.

Table 3. Body mass index values of males and females in the control and diabetic groups. Data presented as mean ± SD.

  Male n Female n Average n

Control 25.21 ± 2.82 1277 25.39 ± 4.83 1769 25.31 ± 4.11 3046Diabetes 27.89 ± 4.14a 1114 29.91 ± 5.76b 1479 29.04 ± 5.22c 2593Average 26.45 ± 3.74 2391 27.44 ± 5.73 3248 27.03 ± 5.01 5639

a Independent sample t-test, 3.72E-115.b Independent sample t-test, 1.52E-68.c Independent sample t-test, 1.85E-174.

950

GÜL et al. / Turk J Med Sci

to complex chronic diseases. GWAS has provided many useful insights into the pathophysiology of type 2 diabetes by enabling the identification of novel susceptibility loci that were not identified by classical approaches. However, for most of the identified type 2 diabetes susceptibility loci, the causal variants and molecular mechanisms for diabetes risk are unknown. Our findings do not reject the importance

of susceptibility loci for causal variants, but rather provide more accurate risk prediction. It is also important to remember that the effect sizes found for SNPs thus far are not a reflection of their biological or clinical significance. Although their individual predictive values may be small, SNPs as a profile might point to important biological pathways that could be targeted for therapeutic intervention.

Table 4. P-value, odds ratio, net reclassification improvement (NRI) percentage, overall prediction percentage, and AUC of phenotypic variables (n/a, not applicable).

Phenotype P-value Odds ratio NRI % Overall prediction % AUC

Baseline n/a n/a n/a 54 n/aBody mass index 5.21E-108 3.86 13.99 68.0 0.68a

Familial diabetes history 4.32E-69 3.10 9.70 63.7 0.63b

High blood pressure 3.25E-39 2.37 9.68 63.7 0.62b

Cholesterol 7.76E-15 1.74 4.40 58.4 0.56

Four phenotypes (BMI+FAMDB+HBP+CHOL) 1.56E-187 n/a 16.70 70.7 0.77c

rs10739592 2.08E-14 1.34 2.84 56.9 0.55

a P < 0.001, significantly higher than other groups except BMI+FAMDB+HBP+CHOL.b P < 0.001, significantly higher than cholesterol and rs10739592.c P < 0.001, significantly higher than others.BMI: Body mass index, FAMDB: familial diabetes history, HBP: high blood pressure, CHOL: cholesterol.

Table 5. Additive binary logistic regression analysis of SNPs grouped according to their P-values obtained in GWAS analysis.NPV: Negative predictive value, PPV: positive predictive value, AUC: area under curve.

SNP groups accordingto their P-values Number of SNPs (n) NPV (percentage

correct for control)PPV (percentage correct for diabetes) Overall % AUC

<1.0E-06 10 75.0 38.7 58.3 0.602<1.0E-05 27 (10+17) 72.8 45.3 60.2 0.636<1.0E-04 118 (91+27) 74.3 59.3 67.4 0.735<1.0E-03 798 (680+118) 90.7 89.1 90.0 0.965

Table 6. Effects of cut-off value on classification correctness and AUC.

ROC cutoff value SNPs (n) NPV PPV Overall % AUC

0.5 798 90.7 89.1 90.0 0.965 ± 0.0020.6 798 94.0 83.7 89.3 0.965 ± 0.0020.7 798 96.8 76.8 87.6 0.965 ± 0.0020.8 798 98.4 67.5 84.2 0.965 ± 0.0020.9 798 99.3 52.6 77.8 0.965 ± 0.002

NPV: Negative predictive value, PPV: positive predictive value, AUC: area under curve.

951

GÜL et al. / Turk J Med Sci

Fortunately, the incidence of type 2 diabetes can be delayed or prevented by maintaining healthy lifestyle behaviors (14). The early identification of population subgroups that are at particularly high risk for type 2 diabetes might facilitate the targeting of prevention efforts to those who might benefit from them the most. Until these findings, genetic associations have not appeared to improve type 2 diabetes risk prediction, which has already been achieved through clinical risk predictors alone.

In the time since the first GWAS data were published in 2007 by the Wellcome Trust Case Control Consortium (20), significant progress has been made and much information has been obtained from GWASs. However, GWAS-based studies to improve clinical decisions are still in their initial stages (21). Previous studies have focused mostly on causative loci rather than the entire risk prediction approach. In addition, the results of risk prediction models are not satisfactory for type 2 diabetes. Nearly 40 susceptible loci have been identified in European and Asian populations, but the heritability of type 2 diabetes remains largely unexplained (22). Only ~10% of the known type 2 diabetes heritability could be explained by the results of a European twin study (23). This evidence suggests that information on a large portion of heritability is missing. Since a statistical P-value of 5 × 10–8 is generally accepted for genome-wide significance (24), previous studies did not use SNPs that had P-values

greater than this. Several limitations of the current approach for GWASs in revealing the missing heritability information have been proposed. One limitation is that the accepted importance threshold level for GWASs (P < 5 × 10–8) may produce type 2 errors (false-negative results). Therefore, many important loci could be obscured among other loci having only borderline associations. In addition, Imamura et al. suggested that the other reason for the low percentage of genetic contribution might be the omission of susceptibility variants that have an MAF value of less than 1% (22). However, our findings do not agree with these suggestions. In this study, we used SNPs that had P-values of greater than 5 × 10–8, accepted 5% as the threshold for MAF, and thereby obtained a higher risk prediction score. The most important reason for the low genetic contribution reported so far is that the use of a small number of SNPs for analysis fails to yield a sufficient composite risk score. We proposed that SNPs that have P-values of less than the detaching point of a distribution (in QQ plot), 1.0E-3 in our study, could contribute to risk prediction. Furthermore, Imamura et al. (22) suggested

Specificity1.0 0.8 0.6 0.4 0.2 0.0

Sens

itivi

ty

1.0

0.8

0.6

0.4

0.2

0.0

Genotype+ Phenotype

Phenotype

Genotype

ROC Curve

Figure 3. ROC plot for the BLR model containing type 2 diabetes and 4 phenotype variants, body mass index, familial diabetes history, high blood pressure, and cholesterol (black line, AUC = 0.77), for the 798 SNP variants (red line, AUC = 0.965) and genotype plus phenotype (blue line, AUC = 0.980).

Table 7. SNPs corresponding to the TCF7L2 gene in our GWAS analysis. The P-values of some SNPs differ between males and females.

SNPP-value

General NHS (Female) HPFS (Male)

rs12255372 4.37E-10 9.72E-05 5.52E-07rs12243326 6.12E-10 1.80E-04 3.47E-07rs4132670 6.53E-10 2.56E-04 1.94E-07rs7901695 8.18E-10 1.53E-04 5.83E-07rs4506565 9.48E-10 1.67E-04 5.92E-07rs11196208 2.40E-05 3.67E-03 2.08E-03rs10885409 2.71E-05 5.33E-03 1.50E-03rs11196205 3.49E-05 5.59E-03 1.91E-03rs4074720 1.30E-04 1.22E-02 3.29E-03rs7077039 1.35E-04 1.50E-02 2.77E-03rs10787472 1.38E-04 1.36E-02 3.09E-03rs6585201 3.96E-04 3.57E-02 2.95E-03rs4073288 3.88E-03 >0.05 1.40E-02rs7901275 4.71E-03 >0.05 2.25E-03rs11196212 7.30E-03 4.39E-02 >0.05rs7917983 7.76E-03 >0.05 2.62E-03rs11196181 2.67E-02 >0.05 >0.05rs12266632 3.28E-02 4.17E-02 >0.05rs11196203 3.39E-02 >0.05 1.64E-02

952

GÜL et al. / Turk J Med Sci

that genome-wide exon (exome) sequencing by next-generation sequencers might help explain the missing heritability. Our findings suggest that this might not be necessary in order to obtain a high risk-prediction score. However, next-generation sequencing technology may help find the exact causative loci near or encompassing the newly discovered SNPs.

Because individual SNPs do not yield adequate prediction scores, combining SNPs to yield composite genotype risk scores has also been tested. In such a simulation study by Janssens et al., risk alleles were weighted according to the type 2 diabetes effect size from the original GWAS; this might not substantially improve the C-statistic for alleles with small effect sizes (odds ratio: 1.10–1.25) (25). However, we found that 680 SNPs with P-values between 1.0E-04 and 1.0E-03 yielded an overall prediction score of 87.7% and AUC of 0.947, while 118 SNPs, with P-values of less than 1.0E-04, yielded an overall prediction score of 67.4% and AUC of 0.735. This shows that a high SNP number is required for higher composite genotype risk scores. However, Janssens et al. used only 40 SNPs. The composite risk score is not equal to the sum of individual SNP scores. Due to the overlapping effect of the risk alleles, we could obtain a higher composite risk score with a higher number of SNPs. However, phenotype risk scores are higher than those of individual SNP scores, i.e. OR is 3.86 for BMI in our study. Thus, small phenotype variables could yield higher scores.

The prediction of an individual’s risk of developing type 2 diabetes is the most anticipated clinical use of genetic information. Prediction values of phenotypic and genotypic characters have been investigated in the Malmö Preventive Project, the Botnia Study (8), the Framingham Offspring Study I (9), the Whitehall II study (10), and the GoDARTS Study (26). These studies examined loci ranging in number from 11 to 20 that were associated with type 2 diabetes. The results of these analyses showed no clear improvement in predictive power when adding the genetic risk score to the established risk prediction models by using phenotypic variables such as age, sex, family history, BMI, fasting glucose level, systolic blood pressure, and lipid profile. Basic demographic, clinical, and laboratory predictors have C-statistics (AUC) ranging from 0.66 in the Rotterdam Study (11) to 0.90 in the Framingham Offspring Study I (9). The C-statistic improves from 0.903 to 0.906 with the addition of a 40-SNP score to the clinical model in the Framingham Offspring Study II (7) and from 0.74 to 0.75 in the larger Malmö Preventive Project (8). In other studies, adding genetic information to phenotype-based risk models did not improve discrimination and showed a maximum increase of only 2% over phenotype in ROC curves (6,10,26). AUC values were equal to or lower than 0.60 for genetic variants alone in these studies

(9–11,26). Therefore, phenotype scores were found to be superior to the scores achieved thus far by using genotype alone.

Genotype-based risk prediction may work better in younger individuals. In the Framingham Offspring II study, the addition of a 40-SNP score to a full clinical model achieved better net reclassification improvement (NRI) among those younger than 50 years old (7). However, the degree of prediction scores obtained from genotype is still below the widely accepted clinical prevention target. The greater contribution of genotype over the prediction value of phenotype for patients at a younger age is expected since phenotype variables are more overt only at middle age or older. The most desirable risk prediction method is one with a higher prediction value at an early age, even in childhood. Therefore, our findings provide an opportunity for risk prediction of type 2 diabetes with high accuracy at an early stage.

A limitation on the use of phenotypic variables is the reduced range of ages and follow-up durations for type 2 diabetes genetic prediction. In previous studies, participants with baseline ages were generally in middle adulthood, and the follow-up period was around 10 years. However, we need a model that can estimate the risk earlier, which should be validated at a young age with a longer prediction time horizon to help achieve early prevention. As noted above, in the Framingham Offspring Study II, the 40-SNP genotype risk score significantly improved NRI in younger participants but not in older ones. Here, we show that genetic risk prediction alone using 798 SNPs could yield higher risk prediction for type 2 diabetes.

Due to the low predictive value of the genetic susceptibility loci of type 2 diabetes so far, alternative GWAS strategies, such as enrichment of genetic effects for improving predictive power (i.e. selecting more severe cases, early onset of disease, and family history of type 2 diabetes), and original GWAS study designs (such as response to an antidiabetic treatment or type 2 diabetes in the presence of extreme obesity) (15,27) have been proposed. Complementary epigenomic approaches such as DNA methylation studies have also been proposed in addition to GWAS (27). However, our strategy of using more SNPs may provide greater risk prediction for type 2 diabetes; therefore, the need for a sophisticated approach to risk prediction could be reviewed. Our approach might be combined with epigenomic, environmental, or other enrichment methods for further insight into type 2 diabetes etiology.

In the future, follow-up studies with a reasonable time period should be designed to evaluate the development of type 2 diabetes using the genotype-based risk prediction value from our study. We were able to calculate individual risk scores using the constants of the present

953

GÜL et al. / Turk J Med Sci

study obtained through analysis. Our findings should be validated by comparing the cumulative type 2 diabetes incidence in low- and high-risk groups in a follow-up study. In addition, interethnic differences should be reviewed from the perspective of our results, since some GWAS studies did not mention the sex of the participants (28,29). Furthermore, our prediction strategy could also be tested for treatment success of type 2 diabetes by establishing a pharmacogenetic investigation of a genome-wide approach. In a previous study, it was found that a SNP, rs11212617, at a locus containing the ataxia telangiectasia mutated gene could explain 2.5% of the variance in the metformin response (30). Variance greater than this can probably be explained using the composite SNP score

approach. Translation of the findings of the present study will provide a gateway into personalized preventive and therapeutic medicine.

In conclusion, we found that genotype-based risk prediction could yield higher risk prediction values when a sufficient number of SNPs are used. This could enable early risk prediction for type 2 diabetes. The growing importance of the threshold P-value in GWAS analysis should be reviewed, depending on the investigation field. Our findings open up new horizons for translating GWAS findings into improved care for patients with diabetes. The value of genotype-based risk prediction alone or in combination with phenotypic variables should be further investigated in follow-up studies for validation.

References

1. Magee MJ, Narayan KM. Global confluence of infectious and non-communicable diseases – the case of type 2 diabetes. Prev Med 2013; 57: 149–151.

2. Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study. Diabetologia 1999; 42: 139–145.

3. Riserus U, Arnlov J, Berglund L. Long-term predictors of insulin resistance: role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 2007; 30: 2928–2933.

4. Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res 2009; 48: 44–51.

5. Muhlenbruch K, Jeppesen C, Joost HG, Boeing H, Schulze MB. The value of genetic information for diabetes risk prediction - differences according to sex, age, family history and obesity. PLoS One 2013; 8: e64307.

6. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, Fumeron F, Froguel P, Vaxillaire M, Cauchi S et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2008; 31: 2056–2061.

7. de Miguel-Yanes JM, Shrader P, Pencina MJ, Fox CS, Manning AK, Grant RW, Dupuis J, Florez JC, D’Agostino RB Sr, Cupples LA et al. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 2011; 34: 121–125.

8. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359: 2220–2232.

9. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, Wilson PW, D’Agostino RB Sr et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359: 2208–2219.

10. Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M, Kivimaki M, Humphries SE. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 2010; 340: b4838.

11. van Hoek M, Dehghan A, Witteman JC, van Duijn CM, Uitterlinden AG, Oostra BA, Hofman A, Sijbrands EJ, Janssens AC. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 2008; 57: 3122–3128.

12. Vaxillaire M, Veslot J, Dina C, Proenca C, Cauchi S, Charpentier G, Tichet J, Fumeron F, Marre M, Meyre D et al. Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. Diabetes 2008; 57: 244–254.

13. Vassy JL, Meigs JB. Is genetic testing useful to predict type 2 diabetes? Best Pract Res Clin Endocrinol Metabol 2012; 26: 189–201.

14. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.

15. Wheeler E, Barroso I. Genome-wide association studies and type 2 diabetes. Briefings in Functional Genomics 2011; 10: 52–60.

16. Florez JC. The genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab 2008; 93: 4633–4642.

17. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci 2010; 1212: 59–77.

18. Blankers M, Koeter MW, Schippers GM. Missing data approaches in eHealth research: simulation study and a tutorial for nonmathematically inclined researchers. J Med Internet Res 2010; 12: e54.

19. Tong Y, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H, Zhang B. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet 2009; 10: 15.

954

GÜL et al. / Turk J Med Sci

20. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661–678.

21. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011; 470: 187–197.

22. Imamura M, Maeda S. Genetics of type 2 diabetes: the GWAS era and future perspectives [Review]. Endocr J 2011; 58: 723–739.

23. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579–589.

24. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356–369.

25. Janssens AC, Moonesinghe R, Yang Q, Steyerberg EW, van Duijn CM, Khoury MJ. The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases. Genet Med 2007; 9: 528–535.

26. Lango H; UK Type 2 Diabetes Genetics Consortium, Palmer CN, Morris AD, Zeggini E, Hattersley AT, McCarthy MI, Frayling TM, Weedon MN. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 2008; 57: 3129–3135.

27. Bell CG, Finer S, Lindgren CM, Wilson GA, Rakyan VK, Teschendorff AE, Akan P, Stupka E, Down TA, Prokopenko I et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One 2010; 5: e14040.

28. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336–1341.

29. Yamauchi T, Hara K, Maeda S, Yasuda K, Takahashi A, Horikoshi M, Nakamura M, Fujita H, Grarup N, Cauchi S et al. A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet 2010; 42: 864–868.

30. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43: 117–120.

1

GÜL et al. / Turk J Med SciA

ppen

dix.

Chr

omos

omes

, P-v

alue

s, od

ds ra

tios,

and

MA

F va

lues

of 7

98 S

NPs

.

#rs

idO

RP

valu

eM

AF

CH

RBP

A1

A2

Entr

ezG

ene

Gen

e Sy

mbo

lG

ene

Nam

e

1rs

4654

582

0,85

135,

28E-

040,

213

146

3014

3T

A55

966

AJA

P1ad

here

ns ju

nctio

ns a

ssoc

iate

d pr

otei

n 1

2rs

1112

1467

0,79

222,

34E-

040,

105

196

2092

0A

T 

  

3rs

2336

381

0,75

599,

28E-

040,

055

111

9316

11G

A53

51PL

OD

1pr

ocol

lage

n-ly

sine,

2-ox

oglu

tara

te 5

-dio

xyge

nase

1

4rs

1158

0525

1,22

55,

35E-

040,

114

114

1195

18C

T 

  

5rs

1495

621,

154

8,72

E-04

0,25

91

1666

7788

TC

1148

19C

ROC

CP3

cilia

ry ro

otle

t coi

led-

coil,

root

letin

pse

udog

ene

3

6rs

6660

946

0,86

117,

63E-

040,

239

118

6061

42G

A 

  

7rs

7529

705

1,13

98,

30E-

040,

380

119

5926

79A

G83

2C

APZ

Bca

ppin

g pr

otei

n (a

ctin

fila

men

t) m

uscl

e Z-

line,

beta

8rs

1049

2998

0,85

858,

99E-

040,

219

119

6454

34T

C83

2C

APZ

Bca

ppin

g pr

otei

n (a

ctin

fila

men

t) m

uscl

e Z-

line,

beta

9rs

1546

263

0,85

418,

28E-

040,

207

119

6460

20A

G83

2C

APZ

Bca

ppin

g pr

otei

n (a

ctin

fila

men

t) m

uscl

e Z-

line,

beta

10rs

6701

048

1,23

77,

70E-

040,

097

129

6760

41G

C 

  

11rs

6704

040

1,29

47,

84E-

040,

065

130

4172

61C

T 

  

12rs

2157

701,

165

3,04

E-04

0,26

81

3735

8560

AC

  

 

13rs

2157

730,

8676

2,84

E-04

0,36

91

3736

8827

TG

  

 

14rs

2157

920,

8748

6,10

E-04

0,37

61

3737

8028

CT

  

 

15rs

2157

910,

8776

8,13

E-04

0,37

51

3737

8878

CT

  

 

16rs

1213

1641

0,84

242,

90E-

040,

198

137

3841

00A

G 

  

17rs

1211

8788

0,82

3,08

E-05

0,19

81

3739

8350

TC

  

 

18rs

1587

578

0,85

182,

23E-

040,

254

137

4013

28C

A 

  

19rs

1157

9242

0,85

469,

45E-

040,

197

147

9879

66G

A 

  

20rs

1158

4807

0,83

041,

28E-

040,

187

147

9930

41T

C 

  

21rs

7833

230,

8723

3,10

E-04

0,46

81

6671

3368

AG

  

 

22rs

6992

530,

8535

2,96

E-05

0,47

61

6671

3736

AG

  

 

23rs

1273

9235

1,23

23,

14E-

040,

119

166

7280

87C

T 

  

24rs

1214

2962

1,24

71,

53E-

040,

118

166

7306

90A

G 

  

25rs

7537

440

1,14

25,

02E-

040,

426

166

8044

95G

T84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

26rs

1373

909

1,14

25,

08E-

040,

426

166

8134

63G

A84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

27rs

6697

088

0,85

958,

66E-

050,

404

166

8173

12C

G84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

28rs

1088

9634

0,87

083,

05E-

040,

414

166

8384

99G

A84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

29rs

6696

927

0,87

032,

89E-

040,

414

166

8429

69T

C84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

30rs

1562

217

0,86

822,

24E-

040,

414

166

8461

54T

C84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

31rs

6656

912

0,86

582,

15E-

040,

405

166

8562

59T

C84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

2

GÜL et al. / Turk J Med Sci32

rs46

5564

80,

8718

3,51

E-04

0,41

51

6688

6897

CT

8425

1SG

IP1

SH3-

dom

ain

GRB

2-lik

e (e

ndop

hilin

) int

erac

ting

prot

ein

1

33rs

9662

943

0,87

625,

82E-

040,

407

166

8937

20C

T84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

34rs

6681

460

0,87

454,

57E-

040,

415

166

8956

45A

G84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

35rs

6694

782

1,13

58,

31E-

040,

457

166

8993

50G

A84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

36rs

6588

215

0,86

942,

56E-

040,

414

166

9145

37A

G84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

37rs

4655

650

0,87

264,

00E-

040,

415

166

9148

74T

C84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

38rs

7542

924

0,86

992,

78E-

040,

414

166

9156

43G

A84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

39rs

4655

506

0,87

173,

60E-

040,

422

166

9233

99G

A84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

40rs

1078

9215

0,87

555,

22E-

040,

413

166

9237

73T

C84

251

SGIP

1SH

3-do

mai

n G

RB2-

like

(end

ophi

lin) i

nter

actin

g pr

otei

n 1

41rs

3449

350,

8661

4,06

E-04

0,32

11

6791

0451

GA

  

 

42rs

1780

731

1,15

9,22

E-04

0,27

41

7910

8612

CT

  

 

43rs

1434

431

1,13

95,

85E-

040,

477

187

9609

18A

G 

  

44rs

2143

992

1,14

15,

19E-

040,

437

194

1096

36C

T30

836

DN

TTIP

2de

oxyn

ucle

otid

yltr

ansf

eras

e, te

rmin

al, i

nter

actin

g pr

otei

n 2

45rs

3789

439

0,85

888,

37E-

040,

220

194

3520

14C

T24

ABC

A4

ATP-

bind

ing

cass

ette

, sub

-fam

ily A

(ABC

1), m

embe

r 4

46rs

3789

442

0,85

384,

95E-

040,

222

194

3540

44C

G24

ABC

A4

ATP-

bind

ing

cass

ette

, sub

-fam

ily A

(ABC

1), m

embe

r 4

47rs

2220

760

1,13

89,

66E-

040,

372

194

9779

31A

G 

  

48rs

3767

273

1,14

92,

96E-

040,

417

110

3173

621

GC

1301

CO

L11A

1co

llage

n, ty

pe X

I, al

pha

1

49rs

1204

6389

1,14

73,

45E-

040,

416

110

3181

688

AC

1301

CO

L11A

1co

llage

n, ty

pe X

I, al

pha

1

50rs

2616

010

1,14

83,

74E-

040,

413

110

3181

905

CT

1301

CO

L11A

1co

llage

n, ty

pe X

I, al

pha

1

51rs

7550

118

1,14

18,

33E-

040,

357

110

3335

690

TC

1301

CO

L11A

1co

llage

n, ty

pe X

I, al

pha

1

52rs

1415

359

1,13

99,

58E-

040,

359

110

3337

029

CT

1301

CO

L11A

1co

llage

n, ty

pe X

I, al

pha

1

53rs

1049

3988

1,14

18,

36E-

040,

356

110

3338

744

GA

1301

CO

L11A

1co

llage

n, ty

pe X

I, al

pha

1

54rs

2761

441

0,87

856,

23E-

040,

493

111

0538

385

GA

3886

62SL

C6A

17so

lute

car

rier f

amily

6, m

embe

r 17

55rs

1942

216

0,86

487,

95E-

040,

262

111

5721

322

AC

  

 

56rs

1543

594

0,84

132,

22E-

040,

204

111

5845

877

AC

  

 

57rs

1157

9824

0,80

345,

29E-

060,

190

114

5469

224

CT

  

 

58rs

1213

3943

1,23

64,

74E-

040,

106

114

5561

705

GC

607

BCL9

B-ce

ll C

LL/ly

mph

oma

9

59rs

1208

517

0,84

269,

76E-

040,

155

118

3539

106

TC

1062

5IV

NS1

ABP

influ

enza

viru

s NS1

A b

indi

ng p

rote

in

60rs

7539

680

1,23

22,

53E-

040,

123

118

6584

179

GC

  

 

61rs

1075

3046

1,25

8,65

E-05

0,12

41

1866

3114

8G

C 

  

62rs

6425

178

1,24

81,

18E-

050,

164

118

6632

905

CG

  

 

63rs

3919

967

1,25

21,

28E-

050,

161

118

6638

225

AC

  

 

64rs

1075

3049

1,24

81,

12E-

050,

165

118

6639

485

AG

  

 

App

endi

x. (C

ontin

ued)

.

3

GÜL et al. / Turk J Med Sci65

rs75

1667

01,

242

1,78

E-05

0,16

41

1866

4230

3T

C 

  

66rs

6667

131

1,25

1,04

E-05

0,16

41

1866

4907

3T

A 

  

67rs

1565

272

1,23

44,

24E-

050,

165

118

6649

670

AG

  

 

68rs

1722

351,

171

1,22

E-04

0,29

61

1867

2699

9C

A 

  

69rs

4313

401

1,13

67,

69E-

040,

499

118

7650

996

AG

  

 

70rs

1180

0563

0,88

118,

25E-

040,

496

118

7698

667

GC

  

 

71rs

4428

892

0,88

067,

86E-

040,

495

118

7719

770

TA

  

 

72rs

1092

2227

0,88

28,

96E-

040,

486

118

7787

128

AG

  

 

73rs

1119

030

0,88

299,

94E-

040,

485

118

7787

822

AG

  

 

74rs

4950

949

0,87

678,

67E-

040,

372

120

1077

185

CT

  

 

75rs

2250

509

0,82

477,

20E-

040,

129

120

1405

593

AG

4608

MYB

PHm

yosin

bin

ding

pro

tein

H

76rs

3408

351,

138

6,34

E-04

0,47

31

2122

3029

8A

G56

29PR

OX

1pr

ospe

ro h

omeo

box

1

77rs

2820

444

0,86

536,

80E-

040,

276

121

7808

443

AG

  

 

78rs

3002

142

0,82

688,

38E-

040,

129

122

0854

685

CT

  

 

79rs

2133

189

0,85

792,

78E-

040,

283

122

0881

065

CT

3750

56M

IA3

mel

anom

a in

hibi

tory

act

ivity

fam

ily, m

embe

r 3

80rs

1716

3358

0,85

923,

42E-

040,

284

122

0887

262

GA

3750

56M

IA3

mel

anom

a in

hibi

tory

act

ivity

fam

ily, m

embe

r 3

81rs

1746

5637

0,86

325,

02E-

040,

281

122

0890

152

AC

3750

56M

IA3

mel

anom

a in

hibi

tory

act

ivity

fam

ily, m

embe

r 3

82rs

1053

316

0,81

194,

82E-

040,

117

122

0906

461

AG

3750

56M

IA3

mel

anom

a in

hibi

tory

act

ivity

fam

ily, m

embe

r 3

83rs

2378

607

0,85

671,

50E-

040,

315

122

0986

518

TG

4008

23FA

M17

7Bfa

mily

with

sequ

ence

sim

ilarit

y 17

7, m

embe

r B

84rs

6429

366

0,87

313,

87E-

040,

426

124

0833

628

TC

  

 

85rs

2362

255

0,81

3,66

E-04

0,12

61

2441

3048

2G

A64

754

SMYD

3SE

T an

d M

YND

dom

ain

cont

aini

ng 3

86rs

7520

116

0,87

197,

19E-

040,

329

124

4271

398

GC

6475

4SM

YD3

SET

and

MYN

D d

omai

n co

ntai

ning

3

87rs

3893

111

0,86

554,

40E-

040,

302

286

9279

5G

A 

  

88rs

1550

105

0,87

917,

11E-

040,

444

220

6135

84T

C 

  

89rs

1189

7611

0,83

66,

05E-

040,

161

220

6387

98C

T 

  

90rs

4666

430

0,83

012,

33E-

040,

173

220

6419

40G

A 

  

91rs

9307

600,

8558

8,79

E-05

0,35

52

2066

9817

CT

  

 

92rs

4666

438

1,15

67,

02E-

040,

264

220

6740

67A

G 

  

93rs

1109

6680

1,15

9,87

E-04

0,27

02

2067

5712

AT

  

 

94rs

3796

064

1,16

5,39

E-04

0,26

02

2070

1799

AG

6434

2H

S1BP

3H

CLS

1 bi

ndin

g pr

otei

n 3

95rs

1016

6174

0,86

853,

97E-

040,

349

220

7024

84A

G64

342

HS1

BP3

HC

LS1

bind

ing

prot

ein

3

96rs

1780

3553

0,87

436,

86E-

040,

356

225

6786

07T

C18

38D

TNB

dyst

robr

evin

, bet

a

97rs

1261

3835

0,87

46,

66E-

040,

356

225

6827

05A

G18

38D

TNB

dyst

robr

evin

, bet

a

App

endi

x. (C

ontin

ued)

.

4

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

98rs

7562

790

1,14

63,

94E-

040,

399

236

5270

59G

T51

232

CRI

M1

cyst

eine

rich

tran

smem

bran

e BM

P re

gula

tor 1

(cho

rdin

-like

)

99rs

2160

367

1,14

83,

09E-

040,

429

236

5351

23G

C51

232

CRI

M1

cyst

eine

rich

tran

smem

bran

e BM

P re

gula

tor 1

(cho

rdin

-like

)

100

rs38

2115

31,

139

6,86

E-04

0,41

72

3660

6626

GT

5123

2C

RIM

1cy

stei

ne ri

ch tr

ansm

embr

ane

BMP

regu

lato

r 1 (c

hord

in-li

ke)

101

rs27

2788

01,

141

5,83

E-04

0,42

92

5240

8156

CT

  

 

102

rs17

7307

800,

8557

4,53

E-04

0,23

62

5241

6883

GA

  

 

103

rs65

4527

40,

8526

3,46

E-04

0,23

32

5249

7718

CT

  

 

104

rs25

5235

60,

8732

3,56

E-04

0,45

92

5250

8248

GA

  

 

105

rs12

6228

110,

8602

2,44

E-04

0,30

32

5264

1453

TC

  

 

106

rs67

2039

01,

139

6,06

E-04

0,46

72

5265

4578

CT

  

 

107

rs13

4302

960,

8517

8,30

E-05

0,31

32

5267

2168

GC

  

 

108

rs17

0431

200,

8574

1,70

E-04

0,31

32

5267

9905

GA

  

 

109

rs18

4303

21,

138

8,27

E-04

0,39

62

5269

4816

AG

  

 

110

rs14

4644

10,

828

2,42

E-04

0,17

02

5315

5170

TC

  

 

111

rs75

7510

71,

228

1,94

E-04

0,13

32

5515

9490

GT

  

 

112

rs46

7236

70,

8309

2,06

E-04

0,17

62

6025

1920

TC

  

 

113

rs17

3297

261,

232,

03E-

040,

129

260

3385

90A

G 

  

114

rs35

9274

1,17

59,

55E-

040,

178

260

3603

85C

G 

  

115

rs17

6621

760,

7373

1,65

E-04

0,05

92

6495

0508

GC

  

 

116

rs12

4709

941,

288

3,02

E-04

0,08

22

6752

8010

AC

  

 

117

rs11

5976

61,

151

8,91

E-04

0,27

32

7231

7749

TC

2323

3EX

OC

6Bex

ocys

t com

plex

com

pone

nt 6

B

118

rs11

5976

41,

159,

47E-

040,

273

272

3178

74A

T23

233

EXO

C6B

exoc

yst c

ompl

ex co

mpo

nent

6B

119

rs10

2217

691,

158

5,05

E-04

0,27

62

7233

2562

TA

2323

3EX

OC

6Bex

ocys

t com

plex

com

pone

nt 6

B

120

rs21

1883

61,

165

2,46

E-04

0,29

22

9652

6699

CT

  

 

121

rs11

1234

061,

147

4,66

E-04

0,36

52

1116

6701

2T

C 

  

122

rs17

7156

880,

8029

2,28

E-04

0,11

32

1150

8955

0G

T57

628

DPP

10di

pept

idyl

-pep

tidas

e 10

(non

-fun

ctio

nal)

123

rs17

7158

670,

7716

2,45

E-04

0,07

82

1150

9685

3C

A57

628

DPP

10di

pept

idyl

-pep

tidas

e 10

(non

-fun

ctio

nal)

124

rs67

0579

01,

175

5,21

E-04

0,21

32

1216

0935

8T

A 

  

125

rs17

0107

800,

8116

4,87

E-04

0,11

32

1245

3127

4G

T12

9684

CN

TNA

P5co

ntac

tin a

ssoc

iate

d pr

otei

n-lik

e 5

126

rs17

5757

910,

8652

6,66

E-04

0,28

32

1298

0241

5T

C 

  

127

rs49

5404

50,

8795

9,06

E-04

0,39

02

1336

9534

0A

C34

4148

NC

KA

P5N

CK

-ass

ocia

ted

prot

ein

5

128

rs17

7863

001,

189

9,41

E-04

0,14

92

1402

5387

2C

A 

  

129

rs13

5542

10,

7852

4,95

E-05

0,11

82

1606

2146

4A

G22

925

PLA

2R1

phos

phol

ipas

e A

2 re

cept

or 1

, 180

kDa

130

rs13

5542

00,

7953

1,12

E-04

0,11

92

1606

2151

7T

C22

925

PLA

2R1

phos

phol

ipas

e A

2 re

cept

or 1

, 180

kDa

5

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

131

rs46

6514

60,

8047

5,34

E-05

0,14

72

1606

2432

9A

C22

925

PLA

2R1

phos

phol

ipas

e A

2 re

cept

or 1

, 180

kDa

132

rs16

8447

420,

7949

1,94

E-05

0,14

82

1606

3953

0T

A 

  

133

rs75

7346

90,

7916

1,27

E-05

0,14

92

1606

5397

3G

A 

  

134

rs31

1139

70,

8201

2,58

E-05

0,20

42

1607

5960

9C

T36

94IT

GB6

inte

grin

, bet

a 6

135

rs12

6925

851,

163

4,91

E-04

0,25

42

1607

8908

7G

A 

  

136

rs10

1811

810,

809

4,03

E-07

0,29

02

1607

9565

7T

C 

  

137

rs29

2575

70,

7906

1,71

E-06

0,18

32

1608

0941

5G

A 

  

138

rs13

0234

771,

176

8,11

E-04

0,19

32

1608

2013

3T

C 

  

139

rs12

6925

880,

8511

2,43

E-05

0,43

52

1608

3242

8C

T 

  

140

rs75

7297

00,

8261

5,97

E-06

0,28

12

1608

4490

2A

G59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

141

rs10

2073

10,

8064

2,45

E-07

0,29

32

1608

5230

1G

A59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

142

rs10

2073

20,

8552

4,42

E-05

0,42

22

1608

5248

5G

A59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

143

rs12

6925

900,

8606

9,21

E-05

0,41

92

1608

6144

3C

G59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

144

rs12

6925

920,

8126

5,95

E-06

0,22

12

1608

7162

7G

T59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

145

rs99

1715

50,

8574

5,20

E-05

0,45

42

1608

7180

5C

A59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

146

rs40

7746

30,

807

3,16

E-06

0,21

82

1608

7448

0A

G59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

147

rs75

9373

00,

8053

2,55

E-06

0,21

82

1608

7970

0T

C59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

148

rs45

8970

50,

806

2,75

E-06

0,21

92

1608

8438

2T

A59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

149

rs43

8628

00,

8605

7,99

E-05

0,44

92

1608

9104

1A

G59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

150

rs46

6401

30,

8334

6,49

E-06

0,33

12

1608

9241

0G

C59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

151

rs10

1653

190,

8585

1,41

E-04

0,33

72

1609

0105

1T

C59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

152

rs45

3815

00,

8508

2,18

E-05

0,45

12

1609

1757

3G

A59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

153

rs92

8779

50,

8055

2,66

E-06

0,21

82

1609

1803

4C

G59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

154

rs67

1852

60,

7817

2,74

E-07

0,19

72

1609

2242

1T

C59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

155

rs11

6936

020,

8048

2,29

E-06

0,21

92

1609

3290

4C

T59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

156

rs10

9299

820,

8021

4,55

E-06

0,19

52

1609

4452

3C

T59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

157

rs12

9985

870,

8344

1,19

E-05

0,30

72

1609

5054

1T

C59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

158

rs75

8710

20,

8384

1,99

E-05

0,30

62

1609

6752

8T

C59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

159

rs46

6432

30,

8711

3,11

E-04

0,42

82

1609

6793

1C

T59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

160

rs13

0093

740,

8469

5,84

E-05

0,30

52

1609

7334

5C

A59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

161

rs67

4279

90,

8377

2,39

E-04

0,19

82

1610

2570

6C

A59

37RB

MS1

RNA

bin

ding

mot

if, si

ngle

stra

nded

inte

ract

ing

prot

ein

1

162

rs67

5256

91,

154,

89E-

040,

327

216

1182

219

CT

  

 

163

rs13

3901

721,

169

1,69

E-04

0,28

72

1612

3384

7C

T 

  

6

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

164

rs12

4732

931,

186,

70E-

050,

287

216

1237

591

CA

  

 

165

rs43

8335

11,

172

1,35

E-04

0,28

62

1612

4241

4A

G 

  

166

rs43

6834

31,

198

4,39

E-06

0,35

32

1612

4289

7C

G 

  

167

rs16

8513

821,

211,

55E-

040,

169

216

6621

721

AG

6323

SCN

1Aso

dium

chan

nel,

volta

ge-g

ated

, typ

e I,

alph

a su

buni

t

168

rs14

0210

80,

8632

6,78

E-04

0,25

72

1769

5797

2G

T 

  

169

rs12

1856

281,

207

4,01

E-05

0,21

92

1793

8921

6C

T 

  

170

rs10

1907

410,

8765

5,27

E-04

0,44

32

1793

9611

7T

C 

  

171

rs12

4773

460,

8777

6,60

E-04

0,44

42

1794

4585

5A

G28

5025

CC

DC

141

coile

d-co

il do

mai

n co

ntai

ning

141

172

rs10

1761

471,

138

6,24

E-04

0,46

62

1843

7878

9G

C 

  

173

rs82

6186

0,87

767,

66E-

040,

397

218

4403

897

GA

  

 

174

rs23

6920

21,

134

9,11

E-04

0,46

82

1846

9431

0T

C 

  

175

rs12

2328

841,

135

8,70

E-04

0,45

42

1847

0963

0G

C 

  

176

rs15

2621

21,

135

8,54

E-04

0,46

02

1847

1910

2A

G 

  

177

rs10

4976

431,

137

6,98

E-04

0,46

22

1847

6102

7T

C 

  

178

rs13

0109

851,

152,

49E-

040,

458

218

4812

923

AG

  

 

179

rs71

9736

1,13

77,

00E-

040,

487

218

4895

389

GA

  

 

180

rs42

4127

91,

236

3,06

E-04

0,11

72

1923

1791

1T

C 

  

181

rs67

3908

01,

216

8,61

E-04

0,11

92

1923

2235

2T

G 

  

182

rs46

7542

50,

8212

6,52

E-04

0,12

42

2047

3417

3A

G 

  

183

rs75

8385

20,

8505

4,74

E-04

0,21

42

2047

6613

2T

G 

  

184

rs10

1980

840,

8448

4,67

E-05

0,29

72

2048

5557

6A

G 

  

185

rs64

3525

21,

229

4,89

E-04

0,11

62

2053

6626

1A

G11

7583

PARD

3Bpa

r-3

part

ition

ing

defe

ctiv

e 3

hom

olog

B (C

. ele

gans

)

186

rs10

7504

11,

227,

58E-

040,

119

220

5372

981

AG

1175

83PA

RD3B

par-

3 pa

rtiti

onin

g de

fect

ive

3 ho

mol

og B

(C. e

lega

ns)

187

rs26

6389

11,

267

9,40

E-04

0,07

82

2082

8156

6A

G 

  

188

rs16

8400

041,

298

8,31

E-04

0,06

42

2083

2519

3A

G15

1195

CC

NYL

1cy

clin

Y-li

ke 1

189

rs75

8573

61,

177,

85E-

040,

213

221

4300

694

TG

7958

2SP

AG

16sp

erm

ass

ocia

ted

antig

en 1

6

190

rs46

7305

40,

8649

1,25

E-04

0,48

72

2237

9610

6A

T 

  

191

rs22

0373

30,

8618

8,41

E-05

0,48

42

2238

0134

5A

G 

  

192

rs10

9330

000,

8657

1,37

E-04

0,48

82

2238

0165

4G

A 

  

193

rs96

9494

0,86

371,

07E-

040,

484

222

3803

302

GA

  

 

194

rs97

0816

0,86

057,

28E-

050,

481

222

3805

584

GA

  

 

195

rs75

9502

91,

218

7,62

E-05

0,16

82

2360

5670

2C

T 

  

196

rs46

6359

61,

203

2,29

E-04

0,16

72

2360

6594

3A

G 

  

7

GÜL et al. / Turk J Med Sci

197

rs46

8559

81,

175

7,98

E-04

0,19

13

3486

93A

C10

752

CH

L1ce

ll ad

hesio

n m

olec

ule

with

hom

olog

y to

L1C

AM

(clo

se

hom

olog

of L

1)

198

rs76

3050

91,

172

8,62

E-04

0,19

53

3491

68G

A10

752

CH

L1ce

ll ad

hesio

n m

olec

ule

with

hom

olog

y to

L1C

AM

(clo

se

hom

olog

of L

1)

199

rs76

4954

41,

243

8,03

E-04

0,09

23

3530

69C

A10

752

CH

L1ce

ll ad

hesio

n m

olec

ule

with

hom

olog

y to

L1C

AM

(clo

se

hom

olog

of L

1)

200

rs64

4292

91,

148

7,55

E-04

0,30

83

5072

993

TC

  

 

201

rs67

7317

91,

148

6,47

E-04

0,32

73

5073

759

AT

  

 

202

rs11

6117

10,

8322

6,51

E-05

0,22

53

8417

494

CT

1002

8842

8LO

C10

0288

428

unch

arac

teriz

ed L

OC

1002

8842

8

203

rs35

9025

0,83

368,

15E-

050,

221

384

2072

9T

C10

0288

428

LOC

1002

8842

8un

char

acte

rized

LO

C10

0288

428

204

rs35

9024

0,84

342,

13E-

040,

224

384

2126

5G

A10

0288

428

LOC

1002

8842

8un

char

acte

rized

LO

C10

0288

428

205

rs35

9033

0,86

9,99

E-04

0,22

73

8431

789

AG

1002

8842

8LO

C10

0288

428

unch

arac

teriz

ed L

OC

1002

8842

8

206

rs35

9032

0,85

495,

74E-

040,

232

384

3237

9C

T10

0288

428

LOC

1002

8842

8un

char

acte

rized

LO

C10

0288

428

207

rs20

8862

00,

8501

4,58

E-04

0,22

33

8435

932

GT

1002

8842

8LO

C10

0288

428

unch

arac

teriz

ed L

OC

1002

8842

8

208

rs11

7120

161,

206

7,15

E-04

0,13

43

9174

613

GC

9901

SRG

AP3

SLIT

-RO

BO R

ho G

TPas

e ac

tivat

ing

prot

ein

3

209

rs12

1859

780,

8598

3,98

E-04

0,27

23

1106

1367

CG

  

 

210

rs21

3050

50,

8432

1,43

E-05

0,36

83

2172

7970

GA

7975

0ZN

F385

Dzi

nc fi

nger

pro

tein

385

D

211

rs48

5834

80,

8554

7,59

E-05

0,35

83

2173

0685

GA

7975

0ZN

F385

Dzi

nc fi

nger

pro

tein

385

D

212

rs48

5835

20,

8526

4,51

E-05

0,37

43

2174

3250

GA

7975

0ZN

F385

Dzi

nc fi

nger

pro

tein

385

D

213

rs98

3082

51,

275

3,53

E-04

0,08

33

3143

1027

AC

  

 

214

rs12

4859

141,

207

7,85

E-04

0,13

33

3143

7904

CT

  

 

215

rs11

9170

100,

8644

7,17

E-04

0,25

93

5418

1107

AG

5579

9C

AC

NA

2D3

calc

ium

chan

nel,

volta

ge-d

epen

dent

, alp

ha 2

/del

ta su

buni

t 3

216

rs67

9422

90,

8528

2,15

E-04

0,26

03

5418

9989

TG

5579

9C

AC

NA

2D3

calc

ium

chan

nel,

volta

ge-d

epen

dent

, alp

ha 2

/del

ta su

buni

t 3

217

rs13

0616

340,

8717

7,75

E-04

0,30

73

5602

9117

CT

2605

9ER

C2

ELK

S/RA

B6-in

tera

ctin

g/C

AST

fam

ily m

embe

r 2

218

rs10

2173

40,

8224

7,23

E-04

0,12

93

5693

8384

TC

5065

0A

RHG

EF3

Rho

guan

ine

nucl

eotid

e ex

chan

ge fa

ctor

(GEF

) 3

219

rs17

2889

930,

8128

3,12

E-04

0,13

13

5694

0107

GA

5065

0A

RHG

EF3

Rho

guan

ine

nucl

eotid

e ex

chan

ge fa

ctor

(GEF

) 3

220

rs46

2606

70,

8091

2,09

E-04

0,13

53

5696

8071

TC

5065

0A

RHG

EF3

Rho

guan

ine

nucl

eotid

e ex

chan

ge fa

ctor

(GEF

) 3

221

rs10

1550

271,

254

1,60

E-04

0,11

83

6025

9909

TG

2272

FHIT

frag

ile h

istid

ine

tria

d

222

rs17

4000

841,

254

1,46

E-04

0,11

73

6026

1426

TC

2272

FHIT

frag

ile h

istid

ine

tria

d

223

rs11

7071

841,

184

2,12

E-04

0,21

53

6231

6084

TC

  

 

224

rs83

1080

0,85

793,

13E-

040,

273

371

5151

91C

G27

086

FOX

P1fo

rkhe

ad b

ox P

1

225

rs83

1081

0,84

931,

91E-

040,

250

371

5152

98A

G27

086

FOX

P1fo

rkhe

ad b

ox P

1

226

rs67

6619

01,

249,

16E-

040,

102

373

8710

82A

T 

  

227

rs29

1475

1,26

16,

23E-

040,

091

373

8835

78C

G 

  

228

rs52

4431

0,86

665,

60E-

040,

296

374

3835

84A

G 

  

App

endi

x. (C

ontin

ued)

.

8

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

229

rs47

1800

0,87

419,

77E-

040,

312

374

3923

34T

C 

  

230

rs65

5148

30,

8779

9,58

E-04

0,36

43

8756

8689

CT

  

 

231

rs98

1514

90,

8716

4,77

E-04

0,36

63

8756

9165

GC

  

 

232

rs98

1634

41,

141

5,71

E-04

0,40

83

1151

6278

0C

T25

4887

ZDH

HC

23zi

nc fi

nger

, DH

HC

-typ

e co

ntai

ning

23

233

rs98

4092

51,

342

7,41

E-04

0,05

43

1165

8254

6G

A 

  

234

rs16

8239

341,

162

9,09

E-04

0,22

83

1168

1837

4A

G 

  

235

rs17

2816

121,

208

8,85

E-04

0,12

23

1206

0668

9C

T57

514

ARH

GA

P31

Rho

GTP

ase

activ

atin

g pr

otei

n 31

236

rs11

3220

21,

216

5,93

E-04

0,12

23

1206

3318

1C

G55

254

TMEM

39A

tran

smem

bran

e pr

otei

n 39

A

237

rs43

1412

40,

8663

6,53

E-04

0,27

83

1272

7032

2A

G54

946

SLC

41A

3so

lute

car

rier f

amily

41,

mem

ber 3

238

rs67

9661

00,

8683

7,97

E-04

0,27

83

1272

8060

3A

G54

946

SLC

41A

3so

lute

car

rier f

amily

41,

mem

ber 3

239

rs23

6501

20,

8541

6,97

E-05

0,34

83

1272

9989

4T

A54

946

SLC

41A

3so

lute

car

rier f

amily

41,

mem

ber 3

240

rs11

7154

741,

171

6,46

E-05

0,35

03

1502

8460

5T

G65

96H

LTF

helic

ase-

like

tran

scrip

tion

fact

or

241

rs76

4616

61,

149

4,62

E-04

0,34

53

1503

0710

2A

G 

  

242

rs67

9216

81,

156,

29E-

040,

307

315

0319

263

CT

  

 

243

rs12

6959

431,

163

9,81

E-04

0,22

53

1509

8810

7A

T38

9161

AN

KU

B1an

kyrin

repe

at a

nd u

biqu

itin

dom

ain

cont

aini

ng 1

244

rs87

7439

0,88

198,

89E-

040,

497

316

9282

596

CT

2733

3G

OLI

M4

golg

i int

egra

l mem

bran

e pr

otei

n 4

245

rs15

2237

80,

8768

5,13

E-04

0,49

63

1692

8323

1G

A27

333

GO

LIM

4go

lgi i

nteg

ral m

embr

ane

prot

ein

4

246

rs10

4908

090,

842

1,64

E-04

0,22

73

1726

9944

9G

A 

  

247

rs21

3101

70,

8595

7,95

E-04

0,24

23

1727

0025

5C

T 

  

248

rs15

6556

70,

8511

4,30

E-04

0,22

43

1727

0685

5A

T 

  

249

rs14

0200

21,

135

8,86

E-04

0,45

13

1851

2548

8A

G10

057

ABC

C5

ATP-

bind

ing

cass

ette

, sub

-fam

ily C

(CFT

R/M

RP),

mem

ber 5

250

rs93

9338

1,14

44,

01E-

040,

446

318

5186

762

GA

1005

7A

BCC

5AT

P-bi

ndin

g ca

sset

te, s

ub-f

amily

C (C

FTR/

MRP

), m

embe

r 5

251

rs10

9373

301,

144

3,64

E-04

0,47

93

1892

2146

0G

A 

  

252

rs76

1334

00,

8474

7,90

E-04

0,17

93

1892

3342

3C

T 

  

253

rs11

9295

980,

8355

2,93

E-04

0,17

93

1892

3595

8T

C 

  

254

rs10

9386

810,

7794

8,69

E-05

0,09

94

8066

769

AG

8444

8A

BLIM

2ac

tin b

indi

ng L

IM p

rote

in fa

mily

, mem

ber 2

255

rs76

6247

71,

138

6,44

E-04

0,48

24

2384

7568

AG

  

 

256

rs11

7267

231,

174

8,07

E-04

0,19

04

2606

5365

TG

  

 

257

rs10

0340

331,

209

1,21

E-04

0,17

64

2607

1049

AC

  

 

258

rs17

2197

041,

168

9,18

E-04

0,20

04

6173

5051

AG

  

 

259

rs13

1508

830,

8059

4,64

E-04

0,10

84

6582

8632

CT

  

 

260

rs17

7503

110,

8294

3,36

E-04

0,15

74

6586

6784

GA

  

 

9

GÜL et al. / Turk J Med Sci26

1rs

6849

315

1,17

39,

60E-

040,

191

483

7959

01A

T79

966

SCD

5st

earo

yl-C

oA d

esat

uras

e 5

262

rs73

7720

40,

8534

2,29

E-04

0,26

14

8872

7430

CT

  

 

263

rs73

7722

50,

8562

3,10

E-04

0,26

24

8872

7547

CT

  

 

264

rs46

9384

60,

8494

1,52

E-04

0,26

24

8872

8693

AC

  

 

265

rs10

0069

781,

258

3,07

E-05

0,13

64

9689

8971

GA

  

 

266

rs76

5712

41,

241

3,38

E-05

0,15

54

9691

4610

CA

  

 

267

rs11

9317

521,

268

1,64

E-05

0,13

54

9693

8876

AT

  

 

268

rs11

9465

521,

244,

24E-

050,

151

496

9400

53A

C 

  

269

rs17

0245

711,

226

1,09

E-04

0,14

74

9694

2220

GA

  

 

270

rs18

3690

01,

173

6,12

E-04

0,20

44

9695

8725

GA

  

 

271

rs10

4339

751,

175

6,58

E-04

0,19

54

9696

0072

GA

  

 

272

rs18

3689

91,

172

8,21

E-04

0,19

54

9696

6126

AG

  

 

273

rs10

0192

641,

173

7,48

E-04

0,20

24

9696

6176

CG

  

 

274

rs17

4734

051,

237

1,54

E-04

0,12

64

9697

0645

AT

  

 

275

rs13

1075

011,

179,

34E-

040,

194

496

9718

22C

T 

  

276

rs17

0248

261,

215

5,54

E-04

0,12

64

9698

3626

CT

  

 

277

rs17

4759

481,

284

3,09

E-05

0,10

94

9700

2780

CG

  

 

278

rs12

5015

861,

174

8,91

E-05

0,30

74

1028

6103

5T

C 

  

279

rs12

5050

431,

177

2,15

E-04

0,24

44

1028

7438

5T

C 

  

280

rs17

5082

890,

7895

1,96

E-04

0,10

44

1063

3448

2A

G54

790

TET2

tet m

ethy

lcyt

osin

e di

oxyg

enas

e 2

281

rs12

6446

251,

204

9,67

E-04

0,13

04

1119

3596

2T

C 

  

282

rs13

1365

210,

8591

9,10

E-05

0,39

24

1444

2501

4T

C 

  

283

rs12

5012

000,

8522

2,20

E-04

0,26

64

1551

7060

0C

A 

  

284

rs76

7985

60,

8773

7,03

E-04

0,40

14

1603

1598

8G

C 

  

285

rs76

8367

10,

8794

8,79

E-04

0,40

14

1603

3466

7A

G 

  

286

rs11

9391

060,

8803

9,63

E-04

0,40

24

1603

3591

1T

C 

  

287

rs10

0500

990,

8766

8,45

E-04

0,35

84

1603

4385

7T

G 

  

288

rs14

3462

11,

151

8,80

E-04

0,27

44

1628

6910

5G

C56

884

FSTL

5fo

llist

atin

-like

5

289

rs76

6037

31,

374

9,21

E-06

0,07

74

1629

1503

3T

C56

884

FSTL

5fo

llist

atin

-like

5

290

rs13

1178

691,

193

3,19

E-05

0,26

94

1899

2324

4G

C 

  

291

rs48

6306

91,

202

1,64

E-05

0,26

34

1899

2806

0A

C 

  

292

rs65

5323

21,

188

2,00

E-04

0,20

64

1899

4710

9G

A 

  

293

rs11

9421

381,

175

2,58

E-04

0,23

84

1899

6918

8G

C 

  

App

endi

x. (C

ontin

ued)

.

10

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

294

rs10

1792

41,

164

9,47

E-04

0,22

05

2029

187

AG

  

 

295

rs10

4912

230,

8729

4,47

E-04

0,39

55

8843

528

CG

  

 

296

rs10

4912

220,

8724

4,18

E-04

0,39

55

8870

497

AG

  

 

297

rs39

60,

8796

8,05

E-04

0,42

85

9668

339

CG

  

 

298

rs25

3091

30,

7781

1,32

E-04

0,09

45

1163

8455

TC

1501

CTN

ND

2ca

teni

n (c

adhe

rin-a

ssoc

iate

d pr

otei

n), d

elta

2

299

rs48

6604

60,

8759

8,30

E-04

0,35

75

2027

0802

AG

  

 

300

rs48

6604

70,

8746

7,19

E-04

0,35

45

2027

0828

CA

  

 

301

rs10

0371

150,

8766

8,77

E-04

0,35

55

2027

2670

GA

  

 

302

rs81

8052

20,

8719

5,26

E-04

0,35

55

2027

4979

CG

  

 

303

rs29

7460

20,

8805

8,66

E-04

0,43

15

2028

6581

CT

  

 

304

rs13

1648

860,

8797

7,06

E-04

0,48

45

2030

2871

TG

  

 

305

rs29

7459

10,

8784

6,79

E-04

0,43

75

2032

5791

CT

  

 

306

rs44

2981

20,

8601

3,48

E-04

0,27

75

2720

9030

CT

  

 

307

rs45

1834

50,

8576

2,68

E-04

0,27

75

2722

1661

AG

  

 

308

rs45

1054

50,

8557

2,17

E-04

0,27

75

2722

5107

CA

  

 

309

rs68

8052

60,

8558

2,22

E-04

0,28

05

2722

7465

TC

  

 

310

rs68

9031

00,

8586

2,95

E-04

0,27

85

2722

9330

AG

  

 

311

rs21

9921

40,

8431

8,33

E-04

0,16

65

2733

8180

CT

  

 

312

rs14

2825

61,

182

4,18

E-04

0,19

85

3830

9217

TG

1335

84EG

FLA

MEG

F-lik

e, fib

rone

ctin

type

III a

nd la

min

in G

dom

ains

313

rs18

3496

71,

228

2,95

E-04

0,12

35

3840

1890

AG

1335

84EG

FLA

MEG

F-lik

e, fib

rone

ctin

type

III a

nd la

min

in G

dom

ains

314

rs43

3638

31,

149

5,91

E-04

0,32

35

3883

1091

AT

  

 

315

rs68

8600

10,

879

6,63

E-04

0,48

35

5222

2194

CT

3672

ITG

A1

inte

grin

, alp

ha 1

316

rs68

6682

30,

8769

5,37

E-04

0,48

45

5222

2328

AG

3672

ITG

A1

inte

grin

, alp

ha 1

317

rs68

7128

60,

8781

5,92

E-04

0,47

95

5222

2513

TC

3672

ITG

A1

inte

grin

, alp

ha 1

318

rs19

7939

80,

8801

7,33

E-04

0,47

35

5223

0084

AG

3672

ITG

A1

inte

grin

, alp

ha 1

319

rs16

8860

340,

7589

3,06

E-04

0,06

75

5601

9613

CT

  

 

320

rs16

8863

640,

7709

5,91

E-04

0,06

85

5615

8101

GA

4214

MA

P3K

1m

itoge

n-ac

tivat

ed p

rote

in k

inas

e ki

nase

kin

ase

1, E

3 ub

iqui

tin

prot

ein

ligas

e

321

rs16

8864

480,

7709

5,91

E-04

0,06

85

5620

6570

GC

4214

MA

P3K

1m

itoge

n-ac

tivat

ed p

rote

in k

inas

e ki

nase

kin

ase

1, E

3 ub

iqui

tin

prot

ein

ligas

e

322

rs16

8864

960,

7772

1,20

E-04

0,09

35

5625

3286

CT

  

 

323

rs77

2635

40,

7451

3,94

E-04

0,05

65

5629

2240

TC

  

 

324

rs77

2537

70,

8078

6,65

E-04

0,10

35

5629

2353

AG

  

 

325

rs78

6699

1,31

58,

76E-

040,

056

564

7112

37A

C11

174

AD

AM

TS6

AD

AM

met

allo

pept

idas

e w

ith th

rom

bosp

ondi

n ty

pe 1

mot

if, 6

11

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

326

rs12

5149

921,

154

6,33

E-04

0,28

25

7555

4502

GT

2298

7SV

2Csy

napt

ic v

esic

le g

lyco

prot

ein

2C

327

rs12

5168

361,

158,

41E-

040,

278

575

5545

24A

G22

987

SV2C

syna

ptic

ves

icle

gly

copr

otei

n 2C

328

rs47

0443

80,

861

1,83

E-04

0,33

95

7698

0795

GA

  

 

329

rs14

2240

60,

8771

5,85

E-04

0,43

35

7698

1162

CA

  

 

330

rs92

9343

31,

134

9,84

E-04

0,46

85

8463

0874

CG

  

 

331

rs38

4662

01,

229

3,40

E-04

0,12

05

1030

1455

2C

G 

  

332

rs68

9225

91,

224

5,65

E-04

0,12

15

1101

1364

1C

A91

137

SLC

25A

46so

lute

car

rier f

amily

25,

mem

ber 4

6

333

rs45

6236

0,87

988,

55E-

040,

413

511

0115

057

GT

9113

7SL

C25

A46

solu

te c

arrie

r fam

ily 2

5, m

embe

r 46

334

rs77

2376

71,

166

9,17

E-04

0,21

65

1101

8268

5C

T 

  

335

rs12

5172

651,

176,

16E-

040,

224

511

0189

680

TC

  

 

336

rs12

6558

151,

191,

58E-

040,

224

511

0196

417

AG

  

 

337

rs13

5029

41,

174

4,86

E-04

0,22

25

1102

0518

0A

C 

  

338

rs24

1624

81,

166

8,16

E-04

0,22

45

1102

0670

5G

A 

  

339

rs11

7456

461,

144

8,64

E-04

0,32

35

1105

2144

2G

A 

  

340

rs93

2682

61,

156

5,05

E-04

0,29

55

1105

2214

5A

G 

  

341

rs93

2702

71,

286

7,69

E-04

0,06

75

1164

1849

6A

T 

  

342

rs93

2716

51,

135

9,62

E-04

0,41

85

1201

6805

6C

T 

  

343

rs48

9528

61,

145

4,64

E-04

0,40

85

1202

0627

4A

G 

  

344

rs68

7855

91,

142

4,69

E-04

0,44

55

1202

3609

1G

A 

  

345

rs13

1653

741,

144

8,02

E-04

0,34

45

1251

7725

7T

G 

  

346

rs31

330

0,84

783,

07E-

040,

225

513

2889

400

CG

2310

5FS

TL4

folli

stat

in-li

ke 4

347

rs21

6050

50,

872

3,34

E-04

0,43

15

1572

9234

6A

C 

  

348

rs77

0921

21,

156

3,08

E-04

0,33

55

1586

9675

5C

T 

  

349

rs68

6160

01,

158

3,38

E-04

0,31

55

1587

5219

3G

C 

  

350

rs68

8769

51,

158

3,08

E-04

0,32

15

1587

5522

3C

G 

  

351

rs45

4036

1,14

29,

82E-

040,

326

517

2486

267

CG

1532

22C

REBR

FC

REB3

regu

lato

ry fa

ctor

352

rs25

5318

1,34

55,

60E-

050,

068

517

2548

635

AG

  

 

353

rs10

4567

810,

8734

4,91

E-04

0,39

66

1612

5021

GA

  

 

354

rs11

5064

41,

168

2,13

E-04

0,27

86

1692

2283

AC

  

 

355

rs68

6269

1,15

52,

84E-

040,

356

616

9226

25G

A 

  

356

rs93

9671

21,

157

5,37

E-04

0,27

66

1692

6604

TC

  

 

357

rs12

4083

31,

145

6,80

E-04

0,34

96

1693

9387

AG

  

 

358

rs93

4844

01,

223

3,45

E-04

0,13

16

2074

9315

TC

5490

1C

DK

AL1

CD

K5

regu

lato

ry su

buni

t ass

ocia

ted

prot

ein

1-lik

e 1

12

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

359

rs77

6739

11,

178

5,69

E-04

0,19

86

2083

3219

CT

5490

1C

DK

AL1

CD

K5

regu

lato

ry su

buni

t ass

ocia

ted

prot

ein

1-lik

e 1

360

rs16

8941

941,

172,

39E-

040,

276

628

7560

62A

T 

  

361

rs25

1647

81,

196

3,64

E-04

0,16

86

3160

6716

AG

  

 

362

rs25

2350

31,

191

7,91

E-04

0,15

26

3162

1538

AC

534

ATP6

V1G

2AT

Pase

, H+

tran

spor

ting,

lyso

som

al 1

3kD

a, V

1 su

buni

t G2

363

rs31

1710

80,

8686

5,92

E-04

0,30

56

3245

0800

CG

  

 

364

rs92

6883

51,

166

2,66

E-04

0,30

36

3253

6093

AG

  

 

365

rs92

6920

20,

8629

3,91

E-04

0,28

96

3255

7501

TC

  

 

366

rs12

2021

970,

8605

1,32

E-04

0,36

36

3920

0945

CT

  

 

367

rs12

1952

320,

866

2,60

E-04

0,36

06

3920

1111

TC

  

 

368

rs13

6186

41,

148,

60E-

040,

371

648

6272

26G

A 

  

369

rs69

1047

61,

184

9,97

E-04

0,16

46

4863

3649

GA

  

 

370

rs64

5862

01,

155

8,94

E-04

0,26

16

4867

8807

CG

  

 

371

rs30

1052

91,

157

7,94

E-04

0,26

26

4870

1049

CT

  

 

372

rs76

1167

1,13

67,

52E-

040,

471

652

2197

67T

C 

  

373

rs12

6682

51,

136

7,75

E-04

0,46

66

5222

1625

TC

  

 

374

rs37

6544

61,

137

7,63

E-04

0,42

86

5224

9629

TA

4172

MC

M3

min

ichr

omos

ome

mai

nten

ance

com

plex

com

pone

nt 3

375

rs12

2046

270,

8179

2,42

E-05

0,20

46

7177

8351

AT

  

 

376

rs93

4280

30,

841

6,73

E-04

0,17

26

7178

1245

CT

  

 

377

rs19

9667

90,

836

6,36

E-05

0,24

16

7178

3440

GC

  

 

378

rs94

4632

30,

8393

1,81

E-04

0,21

66

7178

9723

GA

  

 

379

rs77

3990

80,

7784

9,65

E-04

0,06

76

7209

0767

GT

  

 

380

rs16

8851

020,

8226

2,30

E-04

0,15

76

7534

1319

TC

  

 

381

rs93

4387

71,

277

5,26

E-04

0,07

66

7992

2723

TA

  

 

382

rs64

5409

71,

277

5,05

E-04

0,07

76

7993

4936

TG

  

 

383

rs13

4323

21,

138

7,49

E-04

0,41

56

8218

7051

GA

  

 

384

rs17

4386

481,

138

7,37

E-04

0,41

86

8221

6223

AG

  

 

385

rs11

9663

101,

138

7,49

E-04

0,41

86

8221

7732

GA

  

 

386

rs11

9640

021,

136

9,02

E-04

0,41

86

8221

7840

AT

  

 

387

rs46

4252

20,

8758

5,66

E-04

0,40

76

8224

9727

TG

  

 

388

rs13

4123

00,

882

9,00

E-04

0,48

26

8243

6294

CT

  

 

389

rs93

7385

51,

141

7,74

E-04

0,36

36

1069

2224

8T

G 

  

390

rs48

8282

1,14

8,44

E-04

0,36

36

1069

2380

6A

G 

  

391

rs10

4573

070,

7555

1,56

E-04

0,07

16

1169

2736

4A

G10

0128

327

BET3

LBE

T3 li

ke (S

. cer

evisi

ae)

13

GÜL et al. / Turk J Med Sci39

2rs

1338

980

1,17

4,64

E-04

0,23

26

1183

2556

3A

G 

  

393

rs19

9845

81,

162

7,43

E-04

0,23

96

1183

6725

8G

T22

2553

SLC

35F1

solu

te c

arrie

r fam

ily 3

5, m

embe

r F1

394

rs27

8901

01,

164

6,40

E-04

0,23

96

1183

6817

3T

G22

2553

SLC

35F1

solu

te c

arrie

r fam

ily 3

5, m

embe

r F1

395

rs14

1641

91,

161

7,72

E-04

0,23

96

1183

6908

7T

A22

2553

SLC

35F1

solu

te c

arrie

r fam

ily 3

5, m

embe

r F1

396

rs15

7204

50,

8553

7,19

E-04

0,21

66

1379

7281

0C

T 

  

397

rs93

2191

60,

8315

7,90

E-04

0,13

96

1438

7822

5A

T 

  

398

rs65

7056

20,

8389

4,51

E-04

0,18

16

1438

7950

8A

G 

  

399

rs69

0889

61,

222,

20E-

040,

151

615

6869

074

CA

  

 

400

rs31

7801

0,85

988,

16E-

040,

240

615

9010

196

TC

9412

0SY

TL3

syna

ptot

agm

in-li

ke 3

401

rs69

0249

11,

207

4,71

E-04

0,14

26

1663

8183

6G

T 

  

402

rs47

2248

30,

8304

5,78

E-04

0,14

37

3159

273

CG

  

 

403

rs17

7898

940,

8228

4,66

E-04

0,13

17

6709

622

TG

7559

ZNF1

2zi

nc fi

nger

pro

tein

12

404

rs74

5639

01,

186

2,31

E-04

0,21

77

1478

4079

GC

1607

DG

KB

diac

ylgl

ycer

ol k

inas

e, be

ta 9

0kD

a

405

rs77

8252

90,

8132

3,11

E-04

0,13

27

2726

4316

AG

  

 

406

rs11

7691

561,

244

8,68

E-04

0,09

17

2854

5359

CT

9586

CRE

B5cA

MP

resp

onsiv

e el

emen

t bin

ding

pro

tein

5

407

rs10

2280

721,

148

2,98

E-04

0,42

87

2954

2212

CT

  

 

408

rs47

2293

01,

146

3,77

E-04

0,42

77

2955

2436

AG

  

 

409

rs12

7009

691,

137

7,82

E-04

0,42

57

2955

2772

AC

  

 

410

rs47

2293

21,

166

1,00

E-04

0,35

27

2957

8479

GA

  

 

411

rs17

1599

211,

363,

09E-

040,

051

731

1237

25T

C 

  

412

rs96

4126

1,14

98,

69E-

040,

284

747

6208

28A

G 

  

413

rs21

1364

31,

145,

56E-

040,

482

752

1042

28G

T 

  

414

rs77

8776

90,

8011

1,25

E-04

0,12

67

5296

3068

GC

  

 

415

rs11

7631

920,

8105

6,06

E-04

0,11

07

5300

2660

TC

  

 

416

rs17

7356

710,

7745

1,03

E-05

0,12

67

5303

4984

CT

  

 

417

rs14

0419

80,

8066

1,46

E-04

0,13

07

5405

2372

AG

  

 

418

rs10

2253

890,

8372

4,45

E-04

0,17

17

6297

3655

CA

  

 

419

rs17

1487

520,

7622

2,83

E-04

0,07

87

7509

2000

CT

3092

HIP

1hu

ntin

gtin

inte

ract

ing

prot

ein

1

420

rs44

1677

60,

8519

2,66

E-05

0,43

97

8281

4002

GA

  

 

421

rs26

1898

91,

147

8,54

E-04

0,29

97

9519

3842

CA

  

 

422

rs45

0854

0,87

778,

10E-

040,

392

710

1485

453

TC

1523

CU

X1

cut-

like

hom

eobo

x 1

423

rs12

5382

860,

8597

3,15

E-04

0,28

57

1015

3604

0A

G15

23C

UX

1cu

t-lik

e ho

meo

box

1

424

rs10

2706

140,

876

4,83

E-04

0,45

97

1016

2446

4A

G15

23C

UX

1cu

t-lik

e ho

meo

box

1

App

endi

x. (C

ontin

ued)

.

14

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

425

rs73

4147

51,

179

9,79

E-04

0,16

97

1031

9205

1A

G56

49RE

LNre

elin

426

rs47

3005

21,

166

8,69

E-04

0,21

37

1042

6955

7C

T37

5612

LHFP

L3lip

oma

HM

GIC

fusio

n pa

rtne

r-lik

e 3

427

rs47

3005

31,

171

6,34

E-04

0,21

37

1042

6961

9A

G37

5612

LHFP

L3lip

oma

HM

GIC

fusio

n pa

rtne

r-lik

e 3

428

rs10

2450

310,

8761

8,89

E-04

0,34

67

1172

8569

7C

T83

992

CTT

NBP

2co

rtac

tin b

indi

ng p

rote

in 2

429

rs78

0193

10,

8633

2,49

E-04

0,32

97

1172

9409

4G

C83

992

CTT

NBP

2co

rtac

tin b

indi

ng p

rote

in 2

430

rs10

2709

600,

8641

2,77

E-04

0,32

87

1173

1287

5C

G 

  

431

rs13

5767

41,

173

8,70

E-04

0,19

17

1192

3645

6G

A 

  

432

rs11

7640

461,

171

9,94

E-04

0,18

87

1193

2460

6G

A 

  

433

rs12

7070

081,

136

8,86

E-04

0,40

47

1312

8252

2T

C 

  

434

rs64

6764

30,

8632

5,23

E-04

0,27

47

1356

1438

1T

G 

  

435

rs27

0101

60,

8703

9,73

E-04

0,27

97

1356

2225

4A

C 

  

436

rs25

5504

81,

141

8,64

E-04

0,34

87

1356

2226

6C

T 

  

437

rs36

1445

1,20

87,

34E-

040,

127

714

1838

625

TC

2860

1TR

BV6-

6T

cell

rece

ptor

bet

a va

riabl

e 6-

6

438

rs85

5733

0,86

322,

38E-

040,

333

714

8993

580

AG

  

 

439

rs17

3184

70,

8764

5,00

E-04

0,46

77

1553

4828

3C

T 

  

440

rs19

6885

31,

135

8,65

E-04

0,45

78

9083

722

CA

  

 

441

rs29

2930

11,

146

5,16

E-04

0,36

38

9085

514

GA

  

 

442

rs27

0504

21,

372,

66E-

040,

053

817

3666

32T

C 

  

443

rs11

9897

980,

7405

3,97

E-04

0,05

58

2232

6597

AC

2351

6SL

C39

A14

solu

te c

arrie

r fam

ily 3

9 (z

inc t

rans

port

er),

mem

ber 1

4

444

rs29

7640

50,

8705

4,33

E-04

0,35

88

2491

1831

AG

  

 

445

rs12

6818

370,

8643

9,95

E-04

0,24

98

2719

1888

TG

  

 

446

rs69

9772

80,

8641

9,68

E-04

0,25

08

2719

6000

TA

  

 

447

rs47

3345

30,

8793

7,26

E-04

0,44

38

3377

0287

GA

  

 

448

rs47

3345

60,

8799

7,79

E-04

0,44

38

3377

5901

AG

  

 

449

rs43

8989

00,

8804

8,23

E-04

0,44

28

3377

7560

AG

  

 

450

rs78

2533

70,

8801

8,20

E-04

0,43

18

4162

6394

CT

  

 

451

rs12

5499

020,

8771

6,57

E-04

0,40

58

4162

8416

GA

  

 

452

rs43

1762

10,

8807

9,46

E-04

0,41

08

4163

5738

AG

286

AN

K1

anky

rin 1

, ery

thro

cytic

453

rs10

5042

420,

7733

2,66

E-04

0,07

98

5914

8749

GA

9036

2FA

M11

0Bfa

mily

with

sequ

ence

sim

ilarit

y 11

0, m

embe

r B

454

rs12

6787

280,

8559

6,74

E-04

0,21

88

6290

9278

GA

  

 

455

rs45

6231

00,

7894

3,93

E-05

0,12

78

6320

7496

GC

  

 

456

rs42

6811

80,

8079

2,08

E-04

0,12

58

6321

7632

GA

  

 

457

rs42

5658

70,

8034

1,06

E-04

0,13

28

6321

8545

TC

  

 

15

GÜL et al. / Turk J Med Sci45

8rs

7832

144

0,80

341,

35E-

040,

126

863

2251

35A

G 

  

459

rs10

5043

440,

8093

2,11

E-04

0,12

88

6322

9338

GT

  

 

460

rs16

9285

450,

7521

4,81

E-06

0,10

58

6325

6978

GA

  

 

461

rs78

3395

80,

8204

1,75

E-04

0,15

28

6327

3320

AG

  

 

462

rs16

9286

020,

8151

9,57

E-05

0,15

68

6330

9109

TC

  

 

463

rs10

9572

160,

8109

1,14

E-04

0,14

38

6331

9367

TA

  

 

464

rs13

2784

230,

8768

5,08

E-04

0,48

88

8778

9535

AC

5471

4C

NG

B3cy

clic

nuc

leot

ide

gate

d ch

anne

l bet

a 3

465

rs24

3686

01,

252

5,49

E-04

0,09

28

1038

1122

5A

G 

  

466

rs25

1475

61,

158

8,04

E-04

0,24

78

1191

5112

4A

G21

31EX

T1ex

osto

sin 1

467

rs11

7770

701,

172

7,54

E-04

0,20

08

1410

1954

1T

G83

696

TRA

PPC

9tr

affick

ing

prot

ein

part

icle

com

plex

9

468

rs10

9603

631,

196

5,55

E-04

0,16

29

1190

703

CT

  

 

469

rs13

1933

21,

372,

16E-

040,

055

920

1824

95G

A 

  

470

rs10

8113

301,

228

1,65

E-05

0,20

09

2019

7095

CT

  

 

471

rs10

9644

771,

379,

75E-

050,

060

920

2060

63C

T 

  

472

rs10

4650

481,

244

6,32

E-06

0,19

69

2020

8695

AG

  

 

473

rs49

7739

51,

474

7,64

E-06

0,05

39

2021

6358

GA

  

 

474

rs10

9644

931,

338

2,87

E-04

0,06

19

2022

9840

CT

  

 

475

rs10

9644

951,

376,

32E-

050,

064

920

2352

83C

T 

  

476

rs16

9235

211,

438

1,07

E-05

0,05

89

2025

1635

CT

  

 

477

rs12

5539

481,

351,

14E-

040,

067

920

2531

86G

A 

  

478

rs70

4195

11,

456

6,41

E-06

0,05

79

2026

5354

GC

  

 

479

rs49

7725

11,

371

6,35

E-05

0,06

39

2026

9793

GA

  

 

480

rs13

3007

410,

8262

1,41

E-04

0,17

89

2095

3339

CT

5491

4FO

CA

Dfo

cadh

esin

481

rs10

9664

840,

8278

1,74

E-04

0,16

99

2480

2191

GA

  

 

482

rs67

6484

1,14

17,

52E-

040,

367

925

9539

89C

A 

  

483

rs17

5596

390,

8709

5,63

E-04

0,33

49

2601

1612

AC

  

 

484

rs10

7387

431,

146

4,94

E-04

0,37

19

2602

7974

CT

  

 

485

rs51

1545

0,86

983,

28E-

040,

404

978

5010

10C

T15

8471

PRU

NE2

prun

e ho

mol

og 2

(Dro

soph

ila)

486

rs50

6086

0,84

441,

07E-

040,

257

978

5164

28C

G15

8471

PRU

NE2

prun

e ho

mol

og 2

(Dro

soph

ila)

487

rs49

1798

0,86

823,

00E-

040,

401

978

5199

89T

A15

8471

PRU

NE2

prun

e ho

mol

og 2

(Dro

soph

ila)

488

rs22

0988

21,

256

5,06

E-04

0,09

09

8112

7236

AG

  

 

489

rs20

1355

71,

206

9,56

E-04

0,13

29

1036

1581

5T

A 

  

490

rs64

7906

70,

8569

3,92

E-04

0,25

79

1036

3538

6A

T 

  

App

endi

x. (C

ontin

ued)

.

16

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

491

rs27

8671

60,

8623

6,66

E-04

0,25

79

1036

3634

2C

T 

  

492

rs14

1564

70,

8643

8,06

E-04

0,25

69

1036

3645

5A

T 

  

493

rs10

7398

160,

8619

6,53

E-04

0,25

19

1036

5629

1C

T 

  

494

rs10

7395

921,

342,

08E-

140,

485

912

3011

433

GA

  

 

495

rs10

7601

821,

137

6,75

E-04

0,48

19

1234

5278

2A

G15

3090

DA

B2IP

DA

B2 in

tera

ctin

g pr

otei

n

496

rs74

6835

11,

148,

33E-

040,

369

913

8114

710

TC

1381

51N

AC

C2

NA

CC

fam

ily m

embe

r 2, B

EN a

nd B

TB (P

OZ)

dom

ain

cont

aini

ng

497

rs38

0257

70,

8656

5,18

E-04

0,29

810

1336

1864

CT

5264

PHYH

phyt

anoy

l-CoA

2-h

ydro

xyla

se

498

rs95

6007

1,17

61,

35E-

040,

276

1023

7614

18G

T 

  

499

rs79

2053

51,

147

8,72

E-04

0,30

910

2377

4744

GA

  

 

500

rs12

2460

981,

155

4,55

E-04

0,31

210

2378

6957

GA

  

 

501

rs11

0135

141,

174

1,12

E-04

0,29

110

2379

9607

AG

  

 

502

rs70

8599

91,

141

9,35

E-04

0,34

710

2380

0758

GC

  

 

503

rs79

0025

21,

163

1,62

E-04

0,34

010

2380

2398

GA

  

 

504

rs64

8228

51,

143

7,67

E-04

0,34

810

2380

8719

TC

  

 

505

rs43

3391

41,

156

3,31

E-04

0,32

810

2381

0664

AG

  

 

506

rs64

8228

91,

143

7,67

E-04

0,34

710

2381

6469

TC

  

 

507

rs12

2446

681,

145

7,84

E-04

0,33

710

2384

1366

GA

  

 

508

rs79

1340

11,

154

3,30

E-04

0,34

110

2384

4221

AC

  

 

509

rs18

5611

31,

159

2,23

E-04

0,34

110

2384

4775

TC

  

 

510

rs98

3990

1,15

72,

63E-

040,

342

1023

8463

88G

A 

  

511

rs11

0135

551,

149

9,25

E-04

0,28

410

2385

8933

AG

  

 

512

rs10

7637

900,

8642

9,06

E-04

0,24

410

3083

1361

CG

  

 

513

rs11

5939

430,

8722

4,44

E-04

0,37

710

3358

5087

TC

8829

NRP

1ne

urop

ilin

1

514

rs10

4305

410,

8777

7,30

E-04

0,39

510

5649

4253

AG

  

 

515

rs26

5864

10,

8287

1,29

E-04

0,18

610

5939

4437

GA

  

 

516

rs26

5863

00,

8453

3,09

E-04

0,20

810

5940

9250

AG

  

 

517

rs19

3045

00,

8418

1,74

E-04

0,22

110

5941

0701

TG

  

 

518

rs29

3958

30,

8453

2,19

E-04

0,22

410

5941

2336

TC

  

 

519

rs23

9340

00,

846

2,32

E-04

0,22

510

5941

4510

TG

  

 

520

rs19

3045

50,

8507

3,87

E-04

0,22

310

5941

4530

AG

  

 

521

rs19

3045

60,

8447

2,03

E-04

0,22

410

5941

4551

AG

  

 

522

rs10

7407

250,

8784

9,56

E-04

0,37

110

5946

0061

GA

  

 

17

GÜL et al. / Turk J Med Sci52

3rs

1100

6021

0,87

184,

72E-

040,

377

1059

4607

12C

T 

  

524

rs17

5936

50,

8511

3,68

E-04

0,22

610

5949

0502

AG

  

 

525

rs39

1593

20,

8544

4,70

E-05

0,40

910

8061

1942

CG

5717

8ZM

IZ1

zinc

fing

er, M

IZ-t

ype

cont

aini

ng 1

526

rs81

0517

0,85

333,

08E-

050,

452

1080

6126

26T

C57

178

ZMIZ

1zi

nc fi

nger

, MIZ

-typ

e co

ntai

ning

1

527

rs12

5717

510,

8533

3,05

E-05

0,45

210

8061

2637

GA

5717

8ZM

IZ1

zinc

fing

er, M

IZ-t

ype

cont

aini

ng 1

528

rs70

3982

0,85

676,

72E-

050,

395

1080

6127

27G

A57

178

ZMIZ

1zi

nc fi

nger

, MIZ

-typ

e co

ntai

ning

1

529

rs11

5538

401,

323

7,27

E-04

0,05

410

8226

8160

CT

8161

9TS

PAN

14te

tras

pani

n 14

530

rs17

4151

120,

837

7,52

E-04

0,15

610

9919

4781

AG

5101

3EX

OSC

1ex

osom

e co

mpo

nent

1

531

rs11

1918

410,

8746

3,97

E-04

0,50

010

1056

2960

1C

T 

  

532

rs71

0092

00,

8741

3,81

E-04

0,48

810

1056

3096

8T

C 

  

533

rs10

8839

420,

8699

2,30

E-04

0,48

610

1056

4137

6C

T79

991

OBF

C1

olig

onuc

leot

ide/

olig

osac

char

ide-

bind

ing

fold

cont

aini

ng 1

534

rs12

7658

780,

8699

2,30

E-04

0,48

610

1056

5961

2C

T79

991

OBF

C1

olig

onuc

leot

ide/

olig

osac

char

ide-

bind

ing

fold

cont

aini

ng 1

535

rs14

2150

31,

164

7,37

E-04

0,22

710

1074

8509

0G

A 

  

536

rs21

1199

51,

169,

82E-

040,

226

1010

7497

352

GA

  

 

537

rs10

7870

191,

146

9,79

E-04

0,30

610

1090

5080

8T

G 

  

538

rs28

0461

11,

245

4,64

E-04

0,10

710

1138

3746

2C

T 

  

539

rs28

0461

41,

235

7,72

E-04

0,10

710

1138

4183

1C

T 

  

540

rs40

7472

01,

156

1,30

E-04

0,47

610

1147

3848

7T

C69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

541

rs79

0169

51,

288,

18E-

100,

328

1011

4744

078

CT

6934

TCF7

L2tr

ansc

riptio

n fa

ctor

7-li

ke 2

(T-c

ell s

peci

fic, H

MG

-box

)

542

rs45

0656

51,

278

9,48

E-10

0,33

110

1147

4603

1T

A69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

543

rs41

3267

01,

282

6,53

E-10

0,33

110

1147

5776

1A

G69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

544

rs65

8520

11,

144

3,96

E-04

0,45

910

1147

5877

3A

G69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

545

rs10

7874

721,

155

1,38

E-04

0,47

410

1147

7128

7C

A69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

546

rs12

2433

261,

292

6,12

E-10

0,29

510

1147

7880

5C

T69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

547

rs70

7703

91,

157

1,35

E-04

0,46

710

1147

7906

7C

T69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

548

rs11

1962

051,

173,

49E-

050,

473

1011

4797

037

CG

6934

TCF7

L2tr

ansc

riptio

n fa

ctor

7-li

ke 2

(T-c

ell s

peci

fic, H

MG

-box

)

549

rs10

8854

091,

172

2,71

E-05

0,47

210

1147

9806

2C

T69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

550

rs12

2553

721,

292

4,37

E-10

0,30

210

1147

9889

2T

G69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

551

rs11

1962

081,

173

2,40

E-05

0,47

210

1148

0130

6C

T69

34TC

F7L2

tran

scrip

tion

fact

or 7

-like

2 (T

-cel

l spe

cific

, HM

G-b

ox)

552

rs10

5100

040,

8647

1,97

E-04

0,37

310

1162

1456

9A

G39

83A

BLIM

1ac

tin b

indi

ng L

IM p

rote

in 1

553

rs24

8359

30,

7592

4,89

E-04

0,06

210

1163

5969

6G

A39

83A

BLIM

1ac

tin b

indi

ng L

IM p

rote

in 1

554

rs10

9117

90,

7741

1,03

E-04

0,09

210

1165

5625

8A

G 

  

555

rs24

2092

80,

8735

4,36

E-04

0,40

810

1231

4346

2G

A 

  

App

endi

x. (C

ontin

ued)

.

18

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

556

rs13

2232

80,

8817

9,04

E-04

0,46

610

1239

1109

4C

G10

579

TAC

C2

tran

sfor

min

g, a

cidi

c coi

led-

coil

cont

aini

ng p

rote

in 2

557

rs12

4124

851,

163

6,93

E-04

0,23

410

1317

3159

0T

G 

  

558

rs70

7582

50,

7641

1,83

E-04

0,07

510

1337

2097

9T

C 

  

559

rs11

8272

961,

187

3,63

E-04

0,18

611

3334

236

CT

  

 

560

rs71

0412

81,

232

9,03

E-04

0,10

611

4697

321

TC

  

 

561

rs93

5951

0,82

762,

12E-

040,

166

1159

1814

5T

G 

  

562

rs27

2366

30,

8763

4,90

E-04

0,46

611

6440

086

CA

1061

2TR

IM3

trip

artit

e m

otif

cont

aini

ng 3

563

rs23

0349

30,

8762

5,63

E-04

0,47

411

6455

791

AG

2364

7A

RFIP

2A

DP-

ribos

ylat

ion

fact

or in

tera

ctin

g pr

otei

n 2

564

rs42

7710

30,

7731

7,73

E-05

0,09

711

8345

806

CT

  

 

565

rs18

8182

00,

8518

1,09

E-04

0,29

211

1375

7134

GC

  

 

566

rs23

5104

41,

169

6,83

E-05

0,36

311

1553

5033

AG

  

 

567

rs71

1707

70,

8411

4,65

E-04

0,18

211

1951

0993

CT

8979

7N

AV2

neur

on n

avig

ator

2

568

rs32

9526

1,13

77,

56E-

040,

438

1129

4587

29T

G 

  

569

rs29

2646

10,

8703

7,80

E-04

0,30

311

3420

8169

CT

2584

1A

BTB2

anky

rin re

peat

and

BTB

(PO

Z) d

omai

n co

ntai

ning

2

570

rs29

5752

30,

8663

5,25

E-04

0,30

311

3420

8431

GA

2584

1A

BTB2

anky

rin re

peat

and

BTB

(PO

Z) d

omai

n co

ntai

ning

2

571

rs29

2646

30,

8694

7,23

E-04

0,30

211

3420

8964

GT

2584

1A

BTB2

anky

rin re

peat

and

BTB

(PO

Z) d

omai

n co

ntai

ning

2

572

rs29

5594

90,

863

3,64

E-04

0,30

411

3421

0651

AT

2584

1A

BTB2

anky

rin re

peat

and

BTB

(PO

Z) d

omai

n co

ntai

ning

2

573

rs71

1570

21,

175

9,69

E-05

0,29

111

6178

7955

TA

  

 

574

rs11

6033

831,

174

9,99

E-05

0,29

111

6179

4159

AG

4250

SCG

B2A

2se

cret

oglo

bin,

fam

ily 2

A, m

embe

r 2

575

rs17

7095

521,

245

1,59

E-04

0,11

711

6179

7095

GA

4250

SCG

B2A

2se

cret

oglo

bin,

fam

ily 2

A, m

embe

r 2

576

rs11

2285

060,

8812

8,60

E-04

0,45

811

6864

5758

AG

  

 

577

rs64

4961

0,88

249,

73E-

040,

473

1178

3704

68T

C26

011

OD

Z4od

z, od

d O

z/te

n-m

hom

olog

4 (D

roso

phila

)

578

rs10

7933

500,

8643

1,17

E-04

0,48

311

7837

2163

TC

2601

1O

DZ4

odz,

odd

Oz/

ten-

m h

omol

og 4

(Dro

soph

ila)

579

rs10

7513

010,

8623

9,09

E-05

0,48

511

7837

2286

GC

2601

1O

DZ4

odz,

odd

Oz/

ten-

m h

omol

og 4

(Dro

soph

ila)

580

rs11

2376

750,

8708

2,56

E-04

0,49

011

7837

5191

CT

2601

1O

DZ4

odz,

odd

Oz/

ten-

m h

omol

og 4

(Dro

soph

ila)

581

rs17

3108

751,

207

7,14

E-04

0,13

011

7983

2113

CG

  

 

582

rs11

2324

291,

347

3,79

E-04

0,05

211

8039

7567

TA

  

 

583

rs11

2353

021,

215,

02E-

040,

135

1187

1325

74A

T 

  

584

rs17

1508

521,

263

3,74

E-04

0,08

911

8720

2808

AG

  

 

585

rs17

8335

791,

258

5,03

E-04

0,08

711

8720

3798

CT

  

 

586

rs17

1508

821,

267

2,10

E-04

0,09

511

8721

9070

CT

  

 

587

rs96

6647

91,

202

3,35

E-04

0,16

011

8725

0138

GA

  

 

588

rs71

2125

21,

206

2,52

E-04

0,16

311

8725

6116

CT

  

 

19

GÜL et al. / Turk J Med Sci58

9rs

1939

168

1,17

7,65

E-04

0,21

211

8728

8340

AG

  

 

590

rs71

0186

51,

174

3,13

E-04

0,23

111

8757

7209

AG

  

 

591

rs11

0188

161,

225

8,87

E-05

0,16

011

8757

9357

CT

  

 

592

rs79

3788

21,

225

8,26

E-05

0,15

711

8757

9997

GA

  

 

593

rs41

2205

70,

8374

6,05

E-04

0,16

511

8761

9967

AG

  

 

594

rs11

0200

930,

8564

4,36

E-04

0,24

711

9226

7291

TC

1201

14FA

T3FA

T tu

mor

supp

ress

or h

omol

og 3

(Dro

soph

ila)

595

rs17

1342

781,

246

6,85

E-04

0,09

411

9910

6275

GC

5394

2C

NTN

5co

ntac

tin 5

596

rs45

5971

71,

253

7,39

E-04

0,08

711

1126

5630

9A

G 

  

597

rs16

0022

30,

8376

4,84

E-04

0,16

511

1267

9825

9T

C 

  

598

rs39

3579

40,

7246

4,41

E-05

0,06

311

1278

9588

7G

A21

13ET

S1v-

ets e

ryth

robl

asto

sis v

irus E

26 o

ncog

ene

hom

olog

1 (a

vian

)

599

rs39

3579

50,

7216

3,45

E-05

0,06

411

1278

9600

1C

T21

13ET

S1v-

ets e

ryth

robl

asto

sis v

irus E

26 o

ncog

ene

hom

olog

1 (a

vian

)

600

rs39

3579

60,

7476

2,56

E-04

0,06

111

1278

9613

7A

T21

13ET

S1v-

ets e

ryth

robl

asto

sis v

irus E

26 o

ncog

ene

hom

olog

1 (a

vian

)

601

rs49

3734

20,

7488

2,31

E-04

0,06

311

1279

0351

9G

T21

13ET

S1v-

ets e

ryth

robl

asto

sis v

irus E

26 o

ncog

ene

hom

olog

1 (a

vian

)

602

rs43

3443

0,87

246,

98E-

040,

334

1113

0876

412

AG

5086

3N

TMne

urot

rimin

603

rs18

7019

90,

8733

3,73

E-04

0,44

412

6564

99A

G 

  

604

rs10

8494

640,

8563

6,59

E-05

0,39

112

6594

13A

C 

  

605

rs28

8747

40,

8693

2,37

E-04

0,47

112

6663

92C

T 

  

606

rs10

8489

580,

8312

2,51

E-04

0,17

412

3901

365

TC

  

 

607

rs10

8490

401,

147

3,01

E-04

0,49

812

4312

167

CT

5710

3C

12or

f5ch

rom

osom

e 12

ope

n re

adin

g fr

ame

5

608

rs17

7004

060,

864

1,81

E-04

0,37

812

4332

859

CT

5710

3C

12or

f5ch

rom

osom

e 12

ope

n re

adin

g fr

ame

5

609

rs10

8490

450,

862

1,57

E-04

0,36

812

4337

744

AG

5710

3C

12or

f5ch

rom

osom

e 12

ope

n re

adin

g fr

ame

5

610

rs71

3539

00,

8718

3,18

E-04

0,44

412

2148

9968

TC

7991

2PY

ROX

D1

pyrid

ine

nucl

eotid

e-di

sulp

hide

oxi

dore

duct

ase

dom

ain

1

611

rs11

6109

420,

8747

4,42

E-04

0,44

312

2149

2898

GA

7991

2PY

ROX

D1

pyrid

ine

nucl

eotid

e-di

sulp

hide

oxi

dore

duct

ase

dom

ain

1

612

rs10

8418

431,

176

2,20

E-04

0,24

912

2158

3158

TC

2998

GYS

2gl

ycog

en sy

ntha

se 2

(liv

er)

613

rs10

4921

181,

165

9,48

E-04

0,21

512

2158

3225

TC

2998

GYS

2gl

ycog

en sy

ntha

se 2

(liv

er)

614

rs64

8723

61,

175,

34E-

040,

227

1221

5911

83G

A29

98G

YS2

glyc

ogen

synt

hase

2 (l

iver

)

615

rs10

8418

481,

163

8,61

E-04

0,22

612

2160

0821

AG

2998

GYS

2gl

ycog

en sy

ntha

se 2

(liv

er)

616

rs11

0461

161,

164

8,22

E-04

0,22

612

2160

0886

GC

2998

GYS

2gl

ycog

en sy

ntha

se 2

(liv

er)

617

rs10

7708

361,

166,

93E-

040,

248

1221

6080

08A

G29

98G

YS2

glyc

ogen

synt

hase

2 (l

iver

)

618

rs10

8418

501,

161

6,69

E-04

0,24

812

2160

8123

GA

2998

GYS

2gl

ycog

en sy

ntha

se 2

(liv

er)

619

rs11

0461

221,

159

7,69

E-04

0,25

012

2160

8288

TC

2998

GYS

2gl

ycog

en sy

ntha

se 2

(liv

er)

620

rs10

7837

600,

8774

9,15

E-04

0,35

812

5426

2230

AG

  

 

621

rs47

5917

30,

877

8,81

E-04

0,35

712

5428

7453

AG

  

 

App

endi

x. (C

ontin

ued)

.

20

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

622

rs10

7477

580,

8779

9,48

E-04

0,36

912

5428

7594

TC

  

 

623

rs47

5918

60,

8419

5,66

E-04

0,17

612

5435

0346

AG

  

 

624

rs11

6145

060,

8544

7,92

E-04

0,21

112

5610

1942

CT

  

 

625

rs39

1652

90,

8284

3,60

E-04

0,15

312

6272

1863

GA

5752

2SR

GA

P1SL

IT-R

OBO

Rho

GTP

ase

activ

atin

g pr

otei

n 1

626

rs71

3261

71,

136

9,37

E-04

0,39

212

6348

2244

AG

  

 

627

rs10

8782

111,

143

5,35

E-04

0,39

612

6348

6189

CT

  

 

628

rs38

5160

81,

137

9,35

E-04

0,38

112

6349

5765

GA

  

 

629

rs99

8314

1,14

35,

49E-

040,

392

1263

5066

34G

A23

329

TBC

1D30

TBC

1 do

mai

n fa

mily

, mem

ber 3

0

630

rs12

7555

60,

8717

6,98

E-04

0,32

412

7449

6341

AG

  

 

631

rs99

8137

0,87

496,

75E-

040,

401

1277

4860

27C

G 

  

632

rs12

5826

341,

292

9,45

E-04

0,06

612

8038

5922

TC

8499

PPFI

A2

prot

ein

tyro

sine

phos

phat

ase,

rece

ptor

type

, f p

olyp

eptid

e (P

TPRF

), in

tera

ctin

g pr

otei

n (li

prin

), al

pha

2

633

rs12

8159

880,

7707

1,70

E-04

0,08

312

8218

3441

TC

  

 

634

rs11

1156

630,

7634

9,08

E-05

0,08

412

8218

4765

GA

  

 

635

rs12

5784

180,

7861

4,98

E-04

0,08

312

9508

1078

AG

  

 

636

rs73

0081

51,

301

2,15

E-04

0,07

612

1004

8614

4C

A 

  

637

rs12

5806

321,

205

9,75

E-04

0,13

112

1004

8679

2C

T 

  

638

rs85

5287

0,83

296,

57E-

040,

146

1210

1470

239

AT

  

 

639

rs75

3479

0,83

163,

25E-

040,

163

1210

1482

692

GA

  

 

640

rs10

8608

770,

8429

6,74

E-04

0,17

312

1014

8369

5A

G 

  

641

rs49

6467

11,

145

6,62

E-04

0,34

912

1072

2782

4G

C12

40C

MK

LR1

chem

okin

e-lik

e re

cept

or 1

642

rs10

4004

101,

228

9,70

E-04

0,10

012

1096

7788

2A

G 

  

643

rs11

0675

870,

863

7,45

E-04

0,25

912

1143

3810

7C

T 

  

644

rs12

3133

390,

7823

9,90

E-04

0,07

012

1198

7087

6A

G 

  

645

rs11

0577

650,

8408

8,20

E-04

0,16

112

1237

5938

2C

T 

  

646

rs10

7731

820,

8758

6,21

E-04

0,39

312

1246

8631

2G

T11

4795

TMEM

132B

tran

smem

bran

e pr

otei

n 13

2B

647

rs20

5801

20,

879

7,02

E-04

0,46

212

1246

9336

2G

A11

4795

TMEM

132B

tran

smem

bran

e pr

otei

n 13

2B

648

rs97

9589

0,86

864,

55E-

040,

337

1212

4693

655

TC

1147

95TM

EM13

2Btr

ansm

embr

ane

prot

ein

132B

649

rs38

0315

20,

8741

4,00

E-04

0,45

412

1247

0114

8G

A11

4795

TMEM

132B

tran

smem

bran

e pr

otei

n 13

2B

650

rs38

2538

10,

861

6,46

E-04

0,25

312

1247

0281

6T

C11

4795

TMEM

132B

tran

smem

bran

e pr

otei

n 13

2B

651

rs10

8469

411,

142

4,56

E-04

0,48

312

1247

2039

2T

C 

  

652

rs10

7731

871,

135

7,97

E-04

0,48

412

1247

2408

8G

A 

  

653

rs10

8469

551,

134

8,82

E-04

0,48

712

1247

6271

1T

C 

  

21

GÜL et al. / Turk J Med Sci65

4rs

1084

6980

1,14

34,

13E-

040,

486

1212

4857

508

TG

  

 

655

rs73

1337

10,

8751

9,86

E-04

0,31

912

1248

6103

6A

G 

  

656

rs79

5441

50,

8642

2,46

E-04

0,34

312

1248

6213

4T

C 

  

657

rs91

7334

0,86

752,

41E-

040,

395

1212

4864

111

GA

  

 

658

rs64

8901

90,

8632

1,47

E-04

0,39

312

1248

6683

5A

G 

  

659

rs64

8902

00,

8582

5,91

E-05

0,44

512

1248

6695

6C

T 

  

660

rs64

8902

10,

8455

1,63

E-05

0,40

112

1248

7205

3T

G 

  

661

rs79

7804

51,

193

5,76

E-04

0,15

912

1248

7374

3T

C 

  

662

rs11

0583

691,

188

7,00

E-04

0,16

212

1248

9101

7T

A 

  

663

rs11

6103

910,

8484

1,61

E-05

0,44

112

1248

9465

8T

G 

  

664

rs11

0583

711,

197

3,66

E-05

0,24

812

1248

9476

2A

G 

  

665

rs91

7337

0,85

858,

28E-

050,

393

1212

4903

032

TC

  

 

666

rs11

0585

740,

866

1,44

E-04

0,47

712

1252

5656

9T

C 

  

667

rs10

8471

140,

8648

1,24

E-04

0,48

612

1252

5683

1G

A 

  

668

rs10

7732

450,

8667

1,55

E-04

0,48

612

1252

5705

8A

C 

  

669

rs10

7732

470,

8625

9,24

E-05

0,48

412

1252

6077

9C

T 

  

670

rs10

7442

430,

8624

9,12

E-05

0,48

412

1252

6086

0A

G 

  

671

rs23

4666

90,

8677

1,78

E-04

0,48

312

1252

6411

4G

A 

  

672

rs10

7732

570,

8732

5,11

E-04

0,37

812

1252

9248

3G

A 

  

673

rs20

1048

41,

168

1,36

E-04

0,30

912

1262

9837

8C

G 

  

674

rs10

8479

191,

192

5,42

E-04

0,16

412

1287

0693

9T

C12

1256

TMEM

132D

tran

smem

bran

e pr

otei

n 13

2D

675

rs45

2876

0,88

19,

55E-

040,

416

1212

9326

198

GT

  

 

676

rs17

3571

430,

7415

1,37

E-04

0,06

313

2250

4391

CT

  

 

677

rs54

9305

1,17

98,

55E-

040,

175

1326

0378

76T

G10

810

WA

SF3

WA

S pr

otei

n fa

mily

, mem

ber 3

678

rs18

8881

00,

8314

9,95

E-04

0,14

213

3044

2238

TG

1220

46TE

X26

test

is ex

pres

sed

26

679

rs20

2696

00,

8286

8,28

E-04

0,13

913

3045

8544

CT

  

 

680

rs42

5850

21,

145,

87E-

040,

456

1348

4617

01A

G22

862

FND

C3A

fibro

nect

in ty

pe II

I dom

ain

cont

aini

ng 3

A

681

rs95

6814

31,

148

2,88

E-04

0,45

613

4846

8631

AT

2286

2FN

DC

3Afib

rone

ctin

type

III d

omai

n co

ntai

ning

3A

682

rs49

4279

60,

8653

4,10

E-04

0,31

113

4848

4019

TC

2286

2FN

DC

3Afib

rone

ctin

type

III d

omai

n co

ntai

ning

3A

683

rs93

1642

80,

8733

9,53

E-04

0,31

113

4852

6552

AG

2286

2FN

DC

3Afib

rone

ctin

type

III d

omai

n co

ntai

ning

3A

684

rs14

0782

70,

8688

6,17

E-04

0,30

813

4860

8987

CT

2286

2FN

DC

3Afib

rone

ctin

type

III d

omai

n co

ntai

ning

3A

685

rs19

8380

50,

8704

7,21

E-04

0,31

013

4860

9971

CT

2286

2FN

DC

3Afib

rone

ctin

type

III d

omai

n co

ntai

ning

3A

686

rs95

9124

60,

8627

3,72

E-04

0,30

613

4870

4899

TC

  

 

App

endi

x. (C

ontin

ued)

.

22

GÜL et al. / Turk J Med SciA

ppen

dix.

(Con

tinue

d).

687

rs10

1334

70,

8592

2,95

E-04

0,28

413

4870

8882

TG

  

 

688

rs95

7120

81,

222,

03E-

040,

149

1363

8766

87C

T 

  

689

rs79

9121

01,

188

9,62

E-06

0,39

513

9954

9906

GA

5095

PCC

Apr

opio

nyl C

oA c

arbo

xyla

se, a

lpha

pol

ypep

tide

690

rs91

6048

1,13

89,

35E-

040,

379

1421

8607

60A

C 

  

691

rs37

5148

81,

169,

91E-

040,

224

1422

3739

34A

G12

2704

MRP

L52

mito

chon

dria

l rib

osom

al p

rote

in L

52

692

rs42

4964

1,14

73,

33E-

040,

425

1430

0555

54A

G 

  

693

rs10

1355

621,

186

5,23

E-04

0,18

214

3219

8399

TC

9472

AK

AP6

A k

inas

e (P

RKA

) anc

hor p

rote

in 6

694

rs65

7164

70,

7866

2,51

E-04

0,09

314

3383

6835

GA

  

 

695

rs19

9819

31,

145,

78E-

040,

456

1438

7605

07T

G 

  

696

rs28

5025

091,

142

4,79

E-04

0,45

714

3876

1768

CT

  

 

697

rs13

8775

41,

143

4,85

E-04

0,42

114

6234

1315

CT

2713

3KC

NH

5po

tass

ium

vol

tage

-gat

ed ch

anne

l, su

bfam

ily H

(eag

-rel

ated

), m

embe

r 5

698

rs48

9938

40,

887,

61E-

040,

455

1470

6957

09T

A 

  

699

rs10

4838

371,

205

1,07

E-04

0,19

314

7151

9244

GA

9628

RGS6

regu

lato

r of G

-pro

tein

sign

alin

g 6

700

rs71

5620

01,

176

2,48

E-04

0,24

114

7152

7435

CA

9628

RGS6

regu

lato

r of G

-pro

tein

sign

alin

g 6

701

rs12

8847

771,

177

2,35

E-04

0,24

014

7153

0913

TC

9628

RGS6

regu

lato

r of G

-pro

tein

sign

alin

g 6

702

rs12

8852

581,

197

1,58

E-04

0,19

714

7153

1051

AG

9628

RGS6

regu

lato

r of G

-pro

tein

sign

alin

g 6

703

rs22

8342

21,

184

1,44

E-04

0,23

914

7153

1955

CT

9628

RGS6

regu

lato

r of G

-pro

tein

sign

alin

g 6

704

rs22

8338

10,

805

5,34

E-07

0,25

514

7197

8830

GA

9628

RGS6

regu

lato

r of G

-pro

tein

sign

alin

g 6

705

rs10

4838

450,

846

3,15

E-05

0,34

214

7198

4874

GC

9628

RGS6

regu

lato

r of G

-pro

tein

sign

alin

g 6

706

rs15

4868

70,

8381

5,46

E-05

0,24

814

7202

8222

AG

9628

RGS6

regu

lato

r of G

-pro

tein

sign

alin

g 6

707

rs17

1199

800,

8615

2,01

E-04

0,33

314

7225

3994

AT

8110

DPF

3D

4, zi

nc a

nd d

oubl

e PH

D fi

nger

s, fa

mily

3

708

rs74

0974

0,86

482,

76E-

040,

338

1472

2578

27G

A81

10D

PF3

D4,

zinc

and

dou

ble

PHD

fing

ers,

fam

ily 3

709

rs42

4364

20,

863

2,33

E-04

0,33

514

7225

8454

CG

8110

DPF

3D

4, zi

nc a

nd d

oubl

e PH

D fi

nger

s, fa

mily

3

710

rs17

8084

670,

8227

7,61

E-04

0,12

114

7623

9145

AG

  

 

711

rs11

1592

270,

8498

8,86

E-04

0,18

614

7626

9385

AT

  

 

712

rs17

1092

211,

164

9,72

E-04

0,21

414

7897

9872

TC

9369

NRX

N3

neur

exin

3

713

rs71

4401

11,

165

8,36

E-04

0,21

614

7901

0136

TG

9369

NRX

N3

neur

exin

3

714

rs71

5362

50,

8089

3,27

E-04

0,12

314

7911

9015

AG

9369

NRX

N3

neur

exin

3

715

rs71

5459

90,

815

4,68

E-04

0,12

614

7911

9562

CG

9369

NRX

N3

neur

exin

3

716

rs17

7640

960,

8089

3,01

E-04

0,12

514

7912

0259

TG

9369

NRX

N3

neur

exin

3

717

rs19

0092

0,85

331,

40E-

040,

299

1479

1212

36C

A93

69N

RXN

3ne

urex

in 3

718

rs32

7465

0,86

371,

07E-

040,

494

1480

2997

93C

T14

5508

CEP

128

cent

roso

mal

pro

tein

128

kDa

23

GÜL et al. / Turk J Med Sci71

9rs

2556

611

0,86

461,

19E-

040,

495

1480

4159

19A

G14

5508

CEP

128

cent

roso

mal

pro

tein

128

kDa

720

rs12

0503

420,

8686

2,07

E-04

0,49

214

8043

8617

TC

1455

08C

EP12

8ce

ntro

som

al p

rote

in 1

28kD

a

721

rs28

8803

20,

8678

1,77

E-04

0,50

014

8043

9264

CT

1455

08C

EP12

8ce

ntro

som

al p

rote

in 1

28kD

a

722

rs11

6251

990,

8741

3,73

E-04

0,49

814

8044

2498

AG

1455

08C

EP12

8ce

ntro

som

al p

rote

in 1

28kD

a

723

rs65

7460

80,

8742

3,77

E-04

0,50

014

8044

4575

AC

1455

08C

EP12

8ce

ntro

som

al p

rote

in 1

28kD

a

724

rs10

4447

450,

8628

1,00

E-04

0,47

014

8789

1057

GT

  

 

725

rs11

8489

571,

244

7,53

E-04

0,09

614

9473

1600

CG

7978

9C

LMN

calm

in (c

alpo

nin-

like,

tran

smem

bran

e)

726

rs12

9072

781,

149

2,60

E-04

0,45

115

3176

0469

AG

6263

RYR3

ryan

odin

e re

cept

or 3

727

rs12

5925

421,

141

5,00

E-04

0,45

615

3177

3110

AG

6263

RYR3

ryan

odin

e re

cept

or 3

728

rs16

9625

420,

7151

4,52

E-05

0,05

715

3418

9070

AT

  

 

729

rs71

7095

51,

194

1,32

E-04

0,20

915

4444

4884

CA

  

 

730

rs71

8060

01,

201

5,53

E-04

0,15

115

5085

7433

AG

3175

ON

ECU

T1on

e cu

t hom

eobo

x 1

731

rs10

5186

941,

225

1,58

E-04

0,14

215

5085

9965

AC

3175

ON

ECU

T1on

e cu

t hom

eobo

x 1

732

rs24

5652

61,

215

2,77

E-04

0,14

515

5087

6734

CT

  

 

733

rs10

5191

070,

8559

3,93

E-05

0,48

115

5911

4168

GC

6095

RORA

RAR-

rela

ted

orph

an re

cept

or A

734

rs64

9430

70,

8769

6,36

E-04

0,41

315

6018

1982

GC

  

 

735

rs10

0835

870,

8756

5,60

E-04

0,41

315

6018

5825

TC

  

 

736

rs80

3024

00,

8632

7,29

E-04

0,25

915

6018

6856

TC

  

 

737

rs14

3695

50,

8659

8,85

E-04

0,26

315

6019

1674

TC

  

 

738

rs10

0836

390,

836

1,78

E-04

0,19

315

6836

8811

AG

  

 

739

rs11

0721

560,

8357

1,82

E-04

0,19

115

6836

9472

AT

  

 

740

rs20

5932

21,

246

5,21

E-04

0,10

615

6879

2114

CA

5507

5U

AC

Auv

eal a

utoa

ntig

en w

ith co

iled-

coil

dom

ains

and

ank

yrin

repe

ats

741

rs10

5189

211,

242

6,24

E-04

0,10

515

6879

3963

TC

5507

5U

AC

Auv

eal a

utoa

ntig

en w

ith co

iled-

coil

dom

ains

and

ank

yrin

repe

ats

742

rs71

7797

01,

242

6,51

E-04

0,10

415

6883

2308

GA

5507

5U

AC

Auv

eal a

utoa

ntig

en w

ith co

iled-

coil

dom

ains

and

ank

yrin

repe

ats

743

rs64

9508

11,

139

6,53

E-04

0,43

515

7190

3355

GT

  

 

744

rs22

9027

11,

152

3,43

E-04

0,35

815

8324

8639

CA

9154

SLC

28A

1so

lute

car

rier f

amily

28

(sod

ium

-cou

pled

nuc

leos

ide

tran

spor

ter)

, mem

ber 1

745

rs11

6295

421,

154

1,99

E-04

0,47

215

8789

9758

CG

  

 

746

rs11

6362

100,

8803

8,33

E-04

0,43

415

8941

5484

CT

  

 

747

rs21

3165

90,

8711

2,84

E-04

0,47

515

9892

5810

TG

  

 

748

rs11

2472

260,

8731

3,46

E-04

0,46

815

9893

8486

CT

5518

0LI

NS

lines

hom

olog

(Dro

soph

ila)

749

rs80

3368

90,

8736

4,08

E-04

0,43

415

9895

1820

GC

5518

0LI

NS

lines

hom

olog

(Dro

soph

ila)

750

rs71

8084

40,

8721

3,11

E-04

0,47

315

9895

3582

TC

5518

0LI

NS

lines

hom

olog

(Dro

soph

ila)

App

endi

x. (C

ontin

ued)

.

24

GÜL et al. / Turk J Med Sci75

1rs

8055

183

1,18

35,

50E-

040,

187

1691

9237

TC

6478

8LM

F1lip

ase

mat

urat

ion

fact

or 1

752

rs80

4393

51,

181

6,16

E-04

0,18

316

6306

727

GA

  

 

753

rs12

5972

191,

183

3,83

E-04

0,19

516

6310

627

AC

  

 

754

rs80

6297

51,

191

1,86

E-04

0,20

016

6311

714

TA

  

 

755

rs80

9684

1,20

33,

94E-

050,

227

1663

2243

5A

G 

  

756

rs24

9301

1,20

91,

61E-

040,

165

1693

7740

8T

A 

  

757

rs17

1125

1,28

33,

43E-

050,

110

1634

6184

68T

C 

  

758

rs21

6944

0,87

185,

42E-

040,

356

1658

7988

50A

G 

  

759

rs80

6342

41,

176

5,47

E-04

0,20

816

7842

4987

TC

  

 

760

rs39

2488

91,

202

2,83

E-04

0,17

216

7842

6000

CA

  

 

761

rs80

6204

71,

366

2,18

E-04

0,05

216

7845

7228

GT

  

 

762

rs11

6482

950,

8258

6,97

E-04

0,13

416

8743

2022

TG

2588

GA

LNS

gala

ctos

amin

e (N

-ace

tyl)-

6-su

lfate

sulfa

tase

763

rs16

9648

900,

7752

4,36

E-05

0,10

617

2456

7546

CT

  

 

764

rs11

6521

970,

8246

3,46

E-04

0,15

017

2847

8690

CA

40A

SIC

2ac

id-s

ensin

g (p

roto

n-ga

ted)

ion

chan

nel 2

765

rs22

8768

1,14

39,

15E-

040,

333

1739

5474

19G

T10

014

HD

AC

5hi

ston

e de

acet

ylas

e 5

766

rs19

6839

31,

146

7,52

E-04

0,32

017

4991

9431

AG

  

 

767

rs49

6881

60,

8764

6,27

E-04

0,39

817

6420

0570

GA

  

 

768

rs11

6569

691,

198

5,35

E-04

0,15

017

6982

2772

TC

6444

6D

NA

I2dy

nein

, axo

nem

al, i

nter

med

iate

chai

n 2

769

rs80

7679

41,

142

4,76

E-04

0,46

117

7417

2864

AC

  

 

770

rs65

0123

81,

145,

87E-

040,

460

1774

1813

34T

C 

  

771

rs10

5126

171,

133

9,67

E-04

0,48

717

7420

5146

CG

9267

CY

TH1

cyto

hesin

1

772

rs15

3179

71,

152,

27E-

040,

488

1774

3337

63T

C57

602

USP

36ub

iqui

tin sp

ecifi

c pep

tidas

e 36

773

rs76

7300

1,14

29,

45E-

040,

328

1898

3023

0A

G11

031

RAB3

1RA

B31,

mem

ber R

AS

onco

gene

fam

ily

774

rs47

1999

1,16

2,01

E-04

0,32

918

9834

729

GA

1103

1RA

B31

RAB3

1, m

embe

r RA

S on

coge

ne fa

mily

775

rs55

5935

1,15

32,

39E-

040,

387

1898

3530

7T

C11

031

RAB3

1RA

B31,

mem

ber R

AS

onco

gene

fam

ily

776

rs57

5420

1,13

68,

21E-

040,

421

1898

3837

1A

C11

031

RAB3

1RA

B31,

mem

ber R

AS

onco

gene

fam

ily

777

rs68

8248

1,15

52,

85E-

040,

342

1898

3861

3C

T11

031

RAB3

1RA

B31,

mem

ber R

AS

onco

gene

fam

ily

778

rs50

8816

1,15

12,

54E-

040,

393

1898

3962

0T

C11

031

RAB3

1RA

B31,

mem

ber R

AS

onco

gene

fam

ily

779

rs22

9983

61,

167

1,90

E-04

0,28

718

9840

212

AG

1103

1RA

B31

RAB3

1, m

embe

r RA

S on

coge

ne fa

mily

780

rs55

9655

1,20

22,

26E-

040,

173

1810

0551

23T

C 

  

781

rs37

3736

11,

159

3,64

E-04

0,29

518

1282

1324

CT

5771

PTPN

2pr

otei

n ty

rosin

e ph

osph

atas

e, no

n-re

cept

or ty

pe 2

782

rs99

4701

10,

8569

4,90

E-04

0,24

918

1867

4407

AG

  

 

783

rs65

0732

30,

8509

2,93

E-04

0,24

418

1868

0676

GC

  

 

App

endi

x. (C

ontin

ued)

.

25

GÜL et al. / Turk J Med Sci78

4rs

3911

557

0,84

82,

06E-

040,

246

1818

7265

61T

C 

  

785

rs48

0013

80,

8482

2,15

E-04

0,24

518

1876

8295

GA

5932

RBBP

8re

tinob

last

oma

bind

ing

prot

ein

8

786

rs93

0426

10,

8586

8,68

E-04

0,22

518

1886

0594

TC

5932

RBBP

8re

tinob

last

oma

bind

ing

prot

ein

8

787

rs65

0745

70,

8393

9,33

E-05

0,25

018

1888

0434

TC

  

 

788

rs20

5601

51,

134

8,99

E-04

0,49

218

3216

4600

GT

8020

6FH

OD

3fo

rmin

hom

olog

y 2

dom

ain

cont

aini

ng 3

789

rs16

9737

560,

7505

6,68

E-04

0,05

518

3661

7062

GA

  

 

790

rs72

3486

41,

174

1,57

E-04

0,28

118

5588

5837

TC

  

 

791

rs19

4286

71,

188,

71E-

050,

285

1855

8872

50A

G 

  

792

rs11

6643

271,

173

6,36

E-05

0,34

818

5589

0603

CT

  

 

793

rs80

9152

41,

195,

56E-

050,

267

1855

9029

40C

T 

  

794

rs15

3995

21,

176

1,73

E-04

0,26

618

5591

7492

GA

  

 

795

rs99

6695

11,

148

6,16

E-04

0,33

518

5592

6275

AG

  

 

796

rs65

6715

71,

159

2,35

E-04

0,34

018

5594

1205

GT

  

 

797

rs19

4288

01,

169

1,02

E-04

0,33

918

5594

4189

TC

  

 

798

rs72

3562

61,

162

1,92

E-04

0,33

818

5594

9677

TG

  

 

799

rs17

7823

131,

161

7,07

E-04

0,25

318

5600

2077

CT

  

 

800

rs47

6828

1,16

83,

76E-

040,

258

1856

0035

67C

T 

  

801

rs99

4740

31,

151

4,18

E-04

0,34

918

5602

0730

TC

  

 

802

rs63

9407

1,15

33,

44E-

040,

352

1856

0211

59G

A 

  

803

rs61

9662

1,15

3,05

E-04

0,39

818

5603

5531

AG

  

 

804

rs60

7104

1,14

18,

97E-

040,

355

1856

0425

73G

C 

  

805

rs55

7416

1,14

85,

53E-

040,

347

1856

0460

39G

A 

  

806

rs99

5566

61,

152

5,20

E-04

0,33

618

5606

3765

AG

  

 

807

rs14

2152

11,

139

9,78

E-04

0,34

818

6023

6486

AG

  

 

808

rs47

0443

1,15

85,

80E-

040,

267

1872

8329

68A

G41

55M

BPm

yelin

bas

ic p

rote

in

809

rs48

0525

81,

169

8,10

E-04

0,21

119

3276

3882

AG

  

 

810

rs72

5268

91,

173

6,56

E-04

0,20

219

3308

0647

TC

  

 

811

rs10

1720

71,

176

8,08

E-04

0,18

319

3905

7327

AG

  

 

812

rs72

5121

51,

173

2,09

E-04

0,25

919

3909

9587

GA

  

 

813

rs10

4092

991,

166

9,10

E-04

0,20

819

4101

6164

GA

4868

NPH

S1ne

phro

sis 1

, con

geni

tal,

Finn

ish ty

pe (n

ephr

in)

814

rs41

3329

470,

8161

4,90

E-04

0,12

719

5539

1757

CT

  

 

815

rs28

7640

91,

141

7,11

E-04

0,36

720

1541

5075

AG

1407

33M

AC

ROD

2M

AC

RO d

omai

n co

ntai

ning

2

816

rs37

4647

60,

8168

9,10

E-04

0,10

920

3637

3583

GA

671

BPI

bact

eric

idal

/per

mea

bilit

y-in

crea

sing

prot

ein

App

endi

x. (C

ontin

ued)

.

26

GÜL et al. / Turk J Med Sci81

7rs

6103

249

0,83

257,

24E-

040,

147

2041

3993

50C

T 

  

818

rs60

7305

50,

8728

7,12

E-04

0,33

820

4140

6604

GA

  

 

819

rs16

9852

850,

8374

7,84

E-04

0,15

320

4144

8057

TC

  

 

820

rs61

0371

61,

157

3,05

E-04

0,32

720

4243

3044

CA

3172

HN

F4A

hepa

tocy

te n

ucle

ar fa

ctor

4, a

lpha

821

rs60

6343

81,

183

3,04

E-04

0,20

420

4787

4575

TC

2331

5SL

C9A

8so

lute

car

rier f

amily

9, s

ubfa

mily

A (N

HE8

, cat

ion

prot

on

antip

orte

r 8),

mem

ber 8

822

rs67

6035

1,18

62,

26E-

040,

205

2047

9163

99G

A23

315

SLC

9A8

solu

te c

arrie

r fam

ily 9

, sub

fam

ily A

(NH

E8, c

atio

n pr

oton

an

tipor

ter 8

), m

embe

r 8

823

rs48

7096

1,21

75,

20E-

040,

128

2047

9326

66G

C23

315

SLC

9A8

solu

te c

arrie

r fam

ily 9

, sub

fam

ily A

(NH

E8, c

atio

n pr

oton

an

tipor

ter 8

), m

embe

r 8

824

rs18

8355

31,

193

6,38

E-05

0,24

020

4800

7523

TC

  

 

825

rs60

2017

81,

168

9,91

E-04

0,20

020

4803

7347

CT

6615

SNA

I1sn

ail h

omol

og 1

(Dro

soph

ila)

826

rs22

571,

158

3,47

E-04

0,30

620

5124

5861

GC

1285

53TS

HZ2

teas

hirt

zinc

fing

er h

omeo

box

2

827

rs60

9813

81,

214

7,76

E-04

0,11

920

5270

1411

TC

5581

6D

OK

5do

ckin

g pr

otei

n 5

828

rs14

6805

61,

154

3,96

E-04

0,33

320

5439

9395

CG

6790

AURK

Aau

rora

kin

ase

A

829

rs60

6192

10,

8584

6,35

E-05

0,43

220

5996

6907

CT

  

 

830

rs60

8956

80,

8517

2,69

E-05

0,42

520

5996

7110

AG

  

 

831

rs20

3799

41,

226

8,93

E-04

0,10

521

1588

0541

AC

  

 

832

rs28

2375

91,

245

2,57

E-04

0,11

121

1666

7957

CG

3888

15LI

NC

0047

8lo

ng in

terg

enic

non

-pro

tein

codi

ng R

NA

478

833

rs91

5856

1,24

3,59

E-04

0,11

121

1666

8120

AG

3888

15LI

NC

0047

8lo

ng in

terg

enic

non

-pro

tein

codi

ng R

NA

478

834

rs16

6757

01,

254

1,42

E-04

0,11

221

1666

8591

GA

3888

15LI

NC

0047

8lo

ng in

terg

enic

non

-pro

tein

codi

ng R

NA

478

835

rs38

0220

1,25

2,02

E-04

0,10

921

1666

8953

AG

3888

15LI

NC

0047

8lo

ng in

terg

enic

non

-pro

tein

codi

ng R

NA

478

836

rs36

9347

1,25

31,

44E-

040,

115

2116

6696

62G

A38

8815

LIN

C00

478

long

inte

rgen

ic n

on-p

rote

in co

ding

RN

A 4

78

837

rs15

8046

1,22

4,29

E-04

0,13

221

1831

6684

CT

1405

78C

HO

DL

chon

drol

ectin

838

rs28

2623

90,

8685

5,02

E-04

0,32

621

2070

9622

TG

  

 

839

rs99

8042

70,

873

6,81

E-04

0,34

621

2070

9933

AG

  

 

840

rs28

2624

20,

8687

5,09

E-04

0,32

621

2071

3322

TC

  

 

841

rs19

8505

30,

8615

2,27

E-04

0,32

821

2071

3786

GA

  

 

842

rs28

2624

40,

8668

3,54

E-04

0,34

021

2071

6906

GC

  

 

843

rs10

2925

80,

8229

5,69

E-04

0,13

621

2671

0675

CA

  

 

844

rs28

3105

41,

167

5,52

E-04

0,23

921

2795

4865

AG

  

 

845

rs18

8843

31,

139

8,63

E-04

0,38

621

2795

4964

TC

  

 

846

rs28

3185

41,

162

3,31

E-04

0,28

321

2878

2159

TC

  

 

847

rs28

3186

31,

159

2,21

E-04

0,34

721

2878

8692

TC

  

 

App

endi

x. (C

ontin

ued)

.

27

GÜL et al. / Turk J Med Sci84

8rs

1999

318

1,14

89,

33E-

040,

284

2128

8178

20C

A 

  

849

rs99

7537

11,

215

9,45

E-04

0,11

421

2881

7851

TC

  

 

850

rs11

7010

351,

246

5,68

E-06

0,18

621

3716

2840

AG

3141

HLC

Sho

loca

rbox

ylas

e sy

nthe

tase

(bio

tin-(

prop

riony

l-CoA

-ca

rbox

ylas

e (A

TP-h

ydro

lysin

g)) l

igas

e)

851

rs81

3253

81,

229

2,21

E-05

0,18

321

3719

7902

AG

3141

HLC

Sho

loca

rbox

ylas

e sy

nthe

tase

(bio

tin-(

prop

riony

l-CoA

-ca

rbox

ylas

e (A

TP-h

ydro

lysin

g)) l

igas

e)

852

rs28

3553

01,

237

1,20

E-05

0,18

221

3719

9189

CT

3141

HLC

Sho

loca

rbox

ylas

e sy

nthe

tase

(bio

tin-(

prop

riony

l-CoA

-ca

rbox

ylas

e (A

TP-h

ydro

lysin

g)) l

igas

e)

853

rs28

4581

21,

204

1,09

E-04

0,18

921

3722

0194

TC

3141

HLC

Sho

loca

rbox

ylas

e sy

nthe

tase

(bio

tin-(

prop

riony

l-CoA

-ca

rbox

ylas

e (A

TP-h

ydro

lysin

g)) l

igas

e)

854

rs81

2723

61,

143

8,21

E-04

0,35

321

3727

1007

TC

3141

HLC

Sho

loca

rbox

ylas

e sy

nthe

tase

(bio

tin-(

prop

riony

l-CoA

-ca

rbox

ylas

e (A

TP-h

ydro

lysin

g)) l

igas

e)

855

rs22

0161

0,81

499,

16E-

040,

109

2142

4223

62C

G89

766

UM

OD

L1ur

omod

ulin

-like

1

856

rs99

8145

90,

823

2,92

E-04

0,14

821

4268

1878

GC

6469

9TM

PRSS

3tr

ansm

embr

ane

prot

ease

, ser

ine

3

857

rs24

0116

30,

8312

4,02

E-04

0,15

422

1651

1078

CT

2378

6BC

L2L1

3BC

L2-li

ke 1

3 (a

popt

osis

faci

litat

or)

858

rs25

8710

30,

8412

8,87

E-04

0,15

622

1652

8454

TC

2378

6BC

L2L1

3BC

L2-li

ke 1

3 (a

popt

osis

faci

litat

or)

859

rs71

3999

0,84

141,

07E-

050,

376

2246

2107

76A

G 

  

860

rs60

0822

61,

189

3,71

E-04

0,18

422

4624

3314

CT

  

 

861

rs11

0908

061,

299,

95E-

040,

065

2246

7771

60A

C 

  

862

rs12

0094

341,

181

2,51

E-04

0,32

423

1287

5922

AG

  

 

863

rs59

7978

41,

169

5,82

E-04

0,32

923

1287

6296

CA

  

 

864

rs17

2775

031,

182

8,38

E-04

0,23

923

5683

3086

GA

5506

43LO

C55

0643

unch

arac

teriz

ed L

OC

5506

43

865

rs59

1479

91,

189

5,27

E-04

0,23

923

5684

0879

CT

5506

43LO

C55

0643

unch

arac

teriz

ed L

OC

5506

43

866

rs59

1480

71,

192

4,32

E-04

0,24

023

5686

7944

GT

  

 

867

rs59

6081

11,

191

4,95

E-04

0,23

923

5687

0079

GA

  

 

868

rs19

3097

81,

197

3,48

E-04

0,24

123

5692

7132

TC

  

 

869

rs11

0915

981,

187

6,06

E-04

0,24

023

5692

7696

GT

  

 

870

rs59

1485

21,

186

9,99

E-04

0,21

423

5694

8766

CT

  

 

871

rs43

7957

21,

184

6,85

E-04

0,24

323

5696

8844

GA

  

 

872

rs45

5784

11,

193

2,75

E-04

0,27

423

5738

3907

GT

1585

84FA

AH

2fa

tty a

cid

amid

e hy

drol

ase

2

App

endi

x. (C

ontin

ued)

.

28

GÜL et al. / Turk J Med Sci

873

rs10

8556

220,

8459

5,73

E-04

0,26

723

8590

2249

GC

1171

54D

AC

H2

dach

shun

d ho

mol

og 2

(Dro

soph

ila)

874

rs59

4272

91,

216

9,40

E-04

0,15

523

1081

8127

9A

G 

  

875

rs59

4275

21,

227,

71E-

040,

155

2310

8209

528

GA

  

 

876

rs66

4295

81,

215

9,84

E-04

0,15

423

1082

4927

1G

A 

  

877

rs48

2560

31,

206

8,05

E-04

0,17

723

1177

2789

5C

G 

  

878

rs24

9562

21,

215

5,13

E-04

0,17

623

1177

3702

0G

T 

  

879

rs24

9562

61,

219

4,27

E-04

0,17

423

1177

4294

6T

C 

  

880

rs22

5617

31,

204

9,46

E-04

0,17

423

1177

7361

7C

T35

97IL

13RA

1in

terle

ukin

13

rece

ptor

, alp

ha 1

881

rs29

9705

21,

213

6,24

E-04

0,17

823

1178

0054

8G

A35

97IL

13RA

1in

terle

ukin

13

rece

ptor

, alp

ha 1

882

rs59

6594

70,

8593

5,27

E-04

0,40

823

1447

7723

3C

T 

  

883

rs59

1962

30,

865,

09E-

040,

411

2314

4779

048

CG

  

 

884

rs12

8625

910,

8637

7,72

E-04

0,40

623

1448

0178

2G

T 

  

885

rs12

8611

850,

8554

3,44

E-04

0,40

323

1448

0195

2G

C 

  

886

rs59

6595

50,

8593

4,87

E-04

0,40

623

1448

0758

8A

T 

  

App

endi

x. (C

ontin

ued)

.